<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100923</article-id><article-id pub-id-type="doi">10.7554/eLife.100923</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.100923.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Ferroptosis-related genes mediate tumor microenvironment and prognosis in triple-negative breast cancer via integrated RNA-seq analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gong</surname><given-names>Xuantong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8984-5461</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gu</surname><given-names>Lishuang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0746-5620</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Di</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3521-8371</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Qian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0182-3634</contrib-id><email>754427296@qq.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qin</surname><given-names>Hao</given-names></name><email>haoqin@cicams.ac.cn</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Yong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7682-0433</contrib-id><email>drwangyong77@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02drdmm93</institution-id><institution>Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013xs5b60</institution-id><institution>Department of Ultrasound, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043ek5g31</institution-id><institution>Department of Ultrasound, Affiliated Cancer Hospital of Zhengzhou University</institution></institution-wrap><addr-line><named-content content-type="city">Zhengzhou</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/014gmtw23</institution-id><institution>Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ddfwm68</institution-id><institution>Department of Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023hj5876</institution-id><institution>Dalian University of Technology</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ddfwm68</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>06</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP100923</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-07-04"><day>04</day><month>07</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-07-06"><day>06</day><month>07</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.07.04.602021"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-25"><day>25</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100923.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-12"><day>12</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100923.2"/></event></pub-history><permissions><copyright-statement>© 2024, Gong, Gu et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Gong, Gu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-100923-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-100923-figures-v1.pdf"/><abstract><p>Triple-negative breast cancer (TNBC), an aggressive malignancy with limited tools to predict recurrence and drug sensitivity, exhibits ferroptotic heterogeneity across subtypes. However, the tumor microenvironment (TME) mediated by ferroptosis-related genes remains poorly characterized. This study integrates single-cell and bulk RNA sequencing data from the Gene Expression Omnibus to elucidate ferroptosis-driven TME features in TNBC, employing machine learning to develop prognostic and therapeutic response prediction models. At the single-cell level, T cells were classified into three subpopulations and macrophages into two subpopulations, with their infiltration degrees significantly correlated with clinical outcomes. A risk score model constructed based on these findings demonstrated robust predictive performance, validated in external cohorts with 3-, 4-, and 5-year area under the receiver operating characteristic curves of 0.65, 0.67, and 0.71, respectively. Notably, high-risk patients exhibited enhanced sensitivity to 27 therapeutic agents. By delineating ferroptosis-associated immune heterogeneity, this work provides a risk stratification tool to enhance prognostic precision and therapeutic decision-making in TNBC, while identifying genes offer actionable targets for TNBC precision medicine.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>RNA-seq</kwd><kwd>ferroptosis</kwd><kwd>tumor microenvironment</kwd><kwd>triple-negative breast cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81974268</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82472000</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82304151</award-id><principal-award-recipient><name><surname>Qin</surname><given-names>Hao</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Talent Incentive Program, Cancer Hospital Chinese Academy of Medical Sciences</institution></institution-wrap></funding-source><award-id>801032247</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Cooperation Fund of CHCAMS</institution></institution-wrap></funding-source><award-id>CFA202202023</award-id><principal-award-recipient><name><surname>Qin</surname><given-names>Hao</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>open project of Beijing Key Laboratory of Tumor Invasion and Metastasis Mechanism, Capital Medical University</institution></institution-wrap></funding-source><award-id>2023ZLKF03</award-id><principal-award-recipient><name><surname>Qin</surname><given-names>Hao</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Integrated single-cell RNA-seq analysis identifies ferroptosis-driven tumor microenvironment features, enabling a prognostic risk model and therapeutic targets to advance precision medicine for triple-negative breast cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Global cancer statistics show that breast cancer is the most common cancer in women and the leading cause of cancer deaths (<xref ref-type="bibr" rid="bib7">Bray et al., 2024</xref>). Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Compared with other subtypes, TNBC is highly aggressive, with a poor overall prognosis for patients and a median survival of less than 1 year after recurrent metastasis (<xref ref-type="bibr" rid="bib2">Bardia et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Howlader et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">Keenan and Tolaney, 2020</xref>; <xref ref-type="bibr" rid="bib81">Yam et al., 2021</xref>). Due to the lack of targets for endocrine therapy and targeted therapeutic agents, chemotherapy and emerging immunotherapy are the main therapies. TNBC is highly heterogeneous and only some patients benefit from treatment (<xref ref-type="bibr" rid="bib13">Cortazar et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Kim et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Shepherd et al., 2022</xref>). Unfortunately, there is no effective method that can effectively predict the prognostic risk and drug sensitivity of TNBC, which is an urgent problem in the clinic.</p><p>The tumor microenvironment (TME) is composed of various cell types such as cancer-associated fibroblasts, tumor-associated macrophages, T cells, NK cells, B cells, and endothelial cells, which interact with cancer cells and influence various aspects such as tumor progression, metastasis, and response to therapy (<xref ref-type="bibr" rid="bib4">Binnewies et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Mao et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Mayer et al., 2023</xref>). The composition and functional status of TME vary greatly among different patients with breast cancer, and revealing the TME of each patient is crucial for selecting a reasonable treatment and controlling tumor progression in the long term (<xref ref-type="bibr" rid="bib18">de Visser and Joyce, 2023</xref>; <xref ref-type="bibr" rid="bib84">Yang et al., 2023b</xref>).</p><p>Ferroptosis is an iron-dependent form of non-apoptotic, oxidative form of regulated cell death involving lipid hydroperoxides (<xref ref-type="bibr" rid="bib22">Fang et al., 2023</xref>; <xref ref-type="bibr" rid="bib72">Viswanathan et al., 2017</xref>). Studies have shown that drug-resistant cancer cells are more sensitive to ferroptosis (<xref ref-type="bibr" rid="bib29">Hangauer et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Kim et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Tsoi et al., 2018</xref>). Therefore, ferroptosis is more recognized as a potential target for cancer therapy. Ferroptotic heterogeneity exists in different subtypes of TNBC (<xref ref-type="bibr" rid="bib83">Yang et al., 2023a</xref>). Since ferroptosis is regulated by multiple metabolic pathways, the ferroptosis landscape of TNBC remains unexplored and its relationship with patient prognosis and treatment response is uncertain (<xref ref-type="bibr" rid="bib46">Lu et al., 2022</xref>). Therefore, exploring ferroptosis-related genes in TNBC and their correlation with the immune microenvironment may provide a new treatment trend for TNBC.</p><p>RNA sequencing (RNA-seq) technology is a gene expression analysis method that can qualitatively and quantitatively explore the transcriptome characteristics of biological samples at the tissue and cellular levels (<xref ref-type="bibr" rid="bib31">Hong et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Kuksin et al., 2021</xref>). Single-cell RNA-seq (scRNA-seq) has greatly enhanced our understanding of transcriptional heterogeneity across cell types and states, and can be used to explore the TME (<xref ref-type="bibr" rid="bib45">Li et al., 2024</xref>; <xref ref-type="bibr" rid="bib47">Ma et al., 2023</xref>). Bulk RNA-seq is used to analyze the average expression levels of RNA in tissues or cell populations, and can be utilized to explore differences among individuals (<xref ref-type="bibr" rid="bib10">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Janjic et al., 2022</xref>). Machine learning is a branch of artificial intelligence that enables computer systems to learn from training data and gain experience, and it is increasingly being used for the diagnosis, treatment, and prognostic evaluation of cancer (<xref ref-type="bibr" rid="bib12">Ching et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Guan et al., 2024</xref>). Literature reports that several models have been constructed based on RNA-seq data for the prognostic evaluation of breast cancer patients, but the reproducibility and interpretability of the results still deserve further exploration (<xref ref-type="bibr" rid="bib23">Gao et al., 2024</xref>; <xref ref-type="bibr" rid="bib42">Lei et al., 2022</xref>; <xref ref-type="bibr" rid="bib56">Pei et al., 2023</xref>; <xref ref-type="bibr" rid="bib89">Zhao et al., 2024</xref>). This study intends to further explore the relationship among ferroptosis genes, prognosis, and drug sensitivity from the perspective of ferroptotic heterogeneity in TNBC. In this work, we collected and integrated data from single-cell and bulk RNA-seq to characterize the ferroptosis-related gene mediated TME landscape of TNBC on multiple scales. Furthermore, based on the findings in TME, predictive models of patient prognosis and treatment response were constructed using machine learning algorithms. We hope to provide a new way of individualized risk management for triple-negative breast cancer patients and assist their precision treatment.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The single-cell landscape of TNBC samples</title><p>In this study, a total of nine TNBC single-cell samples were included. After quality control (QC), 38,985 genes from 29,733 cells per sample were finally selected for subsequent analysis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Based on original annotations of data, these cells were divided into 9 major cell clusters and 29 minor cell clusters (<xref ref-type="fig" rid="fig1">Figure 1a–c</xref>). Major cell clusters include B-cells, cancer-associated fibroblasts (CAFs), cancer epithelial, endothelial, myeloid, normal epithelial, plasmablasts, perivascular-like cells (PVL), T-cells. Of these, myeloid cluster is further divided into cycling_myeloid, dendritic cells (DCs), macrophage, and monocyte clusters. As shown in <xref ref-type="fig" rid="fig1">Figure 1c</xref>, the immune microenvironment of TNBC is characterized by a high proportion of T cells and macrophages. On this basis, ligand–receptor interactions between different major cell clusters are frequent (<xref ref-type="fig" rid="fig1">Figure 1d</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Integration and clustering of scRNA-seq data from triple-negative breast cancer.</title><p>(<bold>a</bold>) t-SNE plot of the nine major cell clusters. (<bold>b</bold>) t-SNE plot of the 29 minor cell clusters. (<bold>c</bold>) t-SNE plot of the 12 major cell clusters. (<bold>d</bold>) The number of ligand–receptor interactions of different major cell clusters in cellcell communication network, different colors represent different cell clusters, and arrows represent ligandreceptor orientation. (<bold>e</bold>) Heat map showing the average expression of ferroptosis-related genes in different clinicopathological classifications. (<bold>f</bold>) Heat map showing the average expression of ferroptosis-related genes in different major cell clusters.</p><p><supplementary-material id="fig1scode1"><label>Figure 1—source code 1.</label><caption><title>Single-cell RNA-seq data preprocessing in triple-negative breast cancer.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig1-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Single-cell RNA-seq data preprocessing in triple-negative breast cancer.</title><p>(<bold>a</bold>) Correlation analysis between the number of genes detected per cell and the total RNA molecule count, as well as the proportion of mitochondrial gene expression. (<bold>b</bold>) Violin plots visualizing statistical distributions of gene counts, total RNA molecule counts, mitochondrial gene proportion, and hemoglobin gene proportion across triple-negative breast cancer samples. (<bold>c</bold>) t-SNE plot of samples after batch effect correction.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Of the 471 ferroptosis-related genes from the FerrDb website, 391 were present in the single-cell expression matrix of TNBC. We found that there were significant differences in the average expression of these genes in different clinicopathological classifications, as shown in <xref ref-type="fig" rid="fig1">Figure 1e</xref>. Moreover, there were significant differences in the expression of ferroptosis-related genes in 12 major cell clusters of TNBC (<xref ref-type="fig" rid="fig1">Figure 1f</xref>).</p></sec><sec id="s2-2"><title>Ferroptosis-related subpopulations of T cells in the TNBC</title><p>A total of 11,784T cells in the scRNA-seq data of this study, including cycling T cells, NK cells, NKT cells, T cells CD4+, and T cells CD8+, identified clusters (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Based on the non-negative matrix factorization (NMF) algorithm (rank = 3), each T cell cluster was further categorized into three ferroptosis-related subpopulations (T_C1, T_C2, T_C3). <xref ref-type="fig" rid="fig2">Figure 2b</xref> shows that differentially expressed top 50 ferroptosis-related genes differed significantly among these three subpopulations. Among them, the proportion of NK cells in the T_C2 subpopulation was significantly more than the other two subpopulations (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). According to pseudotime trajectories, we found that all three T cell subpopulations were involved at different periods of differentiation (<xref ref-type="fig" rid="fig2">Figure 2d–f</xref>). Further, <xref ref-type="fig" rid="fig2">Figure 2g</xref> shows the average expression of signature genes associated with 8 functions in 15 subpopulations of T-cells, and we found that gene expression was significantly higher in the cycling T-cells. Moreover, different T-cell subpopulations play an important role in the antitumor process (<xref ref-type="fig" rid="fig2">Figure 2h</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Ferroptosis-related subpopulations of T cells in triple-negative breast cancer.</title><p>(<bold>a</bold>) t-SNE plot of the five identified clusters of T cells. (<bold>b</bold>) Heat map showing the expression of ferroptosis-related genes (top 50) in three subpopulations of T cells. (<bold>c</bold>) Demonstration of the proportion of clusters of T cells in ferroptosis-related subpopulations. (<bold>d</bold>) Pseudotime trajectories showing the developmental time course of T cells. (<bold>e</bold>) Pseudotime trajectories of the five identified clusters of T cells. (<bold>f</bold>) Pseudotime trajectories of ferroptosis-related subpopulations of T cells. (<bold>g</bold>) Heat map showing the average expression of signature genes associated with 8 functions in 15 subpopulations of T-cells. (<bold>h</bold>) Network diagram of the cell–cell communication between cancer epithelial cells and T cells. (<bold>i</bold>) Heat map for differential analysis of transcription factors activity.</p><p><supplementary-material id="fig2scode1"><label>Figure 2—source code 1.</label><caption><title>Ferroptosis-related subpopulations of T cells in triple-negative breast cancer.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig2-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig2-v1.tif"/></fig><p>Transcription factors (TFs) are key regulators in cellular signal transduction (<xref ref-type="bibr" rid="bib25">Gong et al., 2022b</xref>). As a result, RFX5, EOMES, TBX21, CEBPB, RUNX3, and IKZF3 showed higher activities in NKT cells. Besides, IRF, NFATC2, STAT, and PRDM1 showed higher activities in CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="fig2">Figure 2i</xref>). The HALLMARK analysis results revealed a prominent enrichment in pathways such as pathways in DNA−Repair and adipogenesis in cycling T cells, whereas in other clusters of T cells, pathways such as epithelial–mesenchymal transition and KRAS signaling had higher enrichment. However, the difference in enrichment scores between ferroptosis-related subpopulations of T cells was not significant.</p></sec><sec id="s2-3"><title>Ferroptosis-related subpopulations of macrophages in the TNBC</title><p>A total of 3671 macrophages in the scRNA-seq data of this study. Based on the NMF algorithm (rank = 4), two ferroptosis-related subpopulations of macrophages (M_C1, M_C2) were finally obtained after clustering cell clusters with similar markers, and the t-distributed stochastic neighbor embedding (t-SNE) plot is shown in <xref ref-type="fig" rid="fig3">Figure 3a</xref>. The pseudotime trajectories showed that M_C2 cells belong to the early stage of macrophages and then gradually develop into M_C1 cells (<xref ref-type="fig" rid="fig3">Figure 3b and c</xref>). <xref ref-type="fig" rid="fig3">Figure 3d</xref> shows that differentially expressed top 50 ferroptosis-related genes differed significantly among subpopulations.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ferroptosis-related subpopulations of macrophages in triple-negative breast cancer.</title><p>(<bold>a</bold>) t-SNE plot of two ferroptosis-related subpopulations of macrophages. (<bold>b</bold>) Pseudotime trajectories showing the developmental time course of macrophages. (<bold>c</bold>) Pseudotime trajectories of two ferroptosis-related subpopulations of macrophages. (<bold>d</bold>) Heat map showing the average expression of ferroptosis-related genes in two subpopulations of macrophages. (<bold>e</bold>) t-SNE plot showing the expression patterns of marker genes in M_C2. (<bold>f</bold>) t-SNE plot showing the expression patterns of marker genes in M_C1. (<bold>g</bold>) t-SNE plot showing the enrichment score of the TREM2 + MAC in each cell. (<bold>h</bold>) t-SNE plot showing the enrichment score of the FOLR2 + MAC in each cell. (<bold>i</bold>) Bubble plot showing the correlation of enrichment score between TREM2 + MAC and FOLR2 + MAC. (<bold>j</bold>) Network diagram of the cell-cell communication between cancer epithelial cells and ferroptosis-related subpopulations of macrophages.</p><p><supplementary-material id="fig3scode1"><label>Figure 3—source code 1.</label><caption><title>Ferroptosis-related subpopulations of macrophages in triple-negative breast cancer.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig3-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Heat map for differential analysis of transcription factors activity among different subpopulations of macrophages in the triple-negative breast cancer.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Further, we found that FOLR2, SEPP1, MRC1, LYVE1, SLC40A1, and CD163 were highly expressed in M_C1 cells and named M_C1 as FOLR2 + MAC. whereas TREM2, FN1, CXCR4, C3, S100A8, IFI6, and SPP1 were highly expressed in M_C2 and named M_C2 as TREM2 + MAC. <xref ref-type="fig" rid="fig3">Figure 3e and f</xref> shows the marker genes in each subpopulation of macrophages. Enrichment scores of the two subpopulations in each cell are shown by t-SNE plots (<xref ref-type="fig" rid="fig3">Figure 3g and h</xref>). Moreover, the enrichment score of TREM2 + MAC and FOLR2 + MAC were significantly negatively correlated (<italic>r</italic>=−0.779) (<xref ref-type="fig" rid="fig3">Figure 3i</xref>). Communication between these two subpopulations and cancer epithelial cells is vigorous (<xref ref-type="fig" rid="fig3">Figure 3j</xref>). In addition, detection of TFs activity in each macrophage cell revealed that most of TFs had higher activity in FOLR2 + MAC cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p></sec><sec id="s2-4"><title>Construction and validation of predictive survival models based on ferroptosis-related genes</title><p>Based on the recurrence-free survival (RFS) data of TNBC in the GSE25066 database, univariate Cox regression analysis was performed on 8371 specific markers of ferroptosis-related subpopulations, and 41 genes significantly associated with RFS were screened (p&lt;0.01) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). These genes were further analyzed by Least Absolute Shrinkage and Selection Operator (LASSO) regression, and 23 genes were finally selected for the construction of the risk model. We calculate the risk score using the following formula: risk score = TMEM160 * (–0.4689) + EWSR1 * (–0.4237) + BCAT2 * (–0.2346) + PNKP * (–0.1592) + MLEC * (–0.1567) + SAP30BP * (–0.1469) + TBL1XR1 * (–0.0894) + STAG1 * (–0.0695) + NR4A1 * (–0.0630) + TNFRSF9 + (–0.0503) + PSD3 * (–0.0153) + BAD * (–0.0094) + MIIP * 0.0104 + HIST3H2A * 0.0294 + CDC25B * 0.0528 + TCEB1 * 0.0670 + HMGCS1 * 0.0988 + SPC25 * 0.1317 + TKT * 0.2234 + PTTG1 * 0.2960 + ADA * 0.3097 + AK1 * 0.4003 + AIMP2 * 0.4081 (<xref ref-type="fig" rid="fig4">Figure 4a–c</xref>). All patients were categorized into low- and high-risk groups according to the median value of the risk score (<xref ref-type="fig" rid="fig4">Figure 4d–f</xref>). Survival curves showed that patients in the high-risk group had a shorter RFS compared to patients in the low-risk group (p&lt;0.05, <xref ref-type="fig" rid="fig4">Figure 4g</xref>). In addition, the risk score had an excellent predictive effect in predicting RFS in TNBC patients, its area under the receiver operating characteristic curves (AUCs) for 3, 4, and 5 years RFS were 0.87, 0.88, and 0.88 (<xref ref-type="fig" rid="fig4">Figure 4h</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Prognostic differences in triple-negative breast cancer with ferroptosis-related subpopulations.</title><p>(<bold>a</bold>) Least Absolute Shrinkage and Selection Operator (LASSO) regression of 23 ferroptosis-related genes. (<bold>b</bold>) Cross-validation for optimizing the parameter in LASSO regression. (<bold>c</bold>) Demonstration of regression coefficients corresponding to 23 genes. (<bold>d</bold>) Graph showing risk scores for all samples. (<bold>e</bold>) Scatterplot showing recurrence-free survival for all samples. (<bold>f</bold>) Heat map showing the average expression of 23 genes in the low- and high-risk groups. (<bold>g</bold>) Kaplan–Meier curves of survival analysis in the low- and high-risk groups. (<bold>h</bold>) Receiver operating characteristic curves for predicting the recurrence-free survival at 3, 4, and 5 years in training set. (<bold>i</bold>) Receiver operating characteristic curves for predicting the recurrence-free survival at 3, 4 and 5 years in external validation set.</p><p><supplementary-material id="fig4scode1"><label>Figure 4—source code 1.</label><caption><title>Prognostic differences in triple-negative breast cancer with ferroptosis-related subpopulations.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig4-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The forest plot of the top 20 ferroptosis-related genes significantly associated with disease-free survival based on univariate Cox regression analysis (p0.01).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig4-figsupp1-v1.tif"/></fig></fig-group><p>In external validation set (GSE86166), patients in the high-risk group also had a shorter RFS compared to patients in the low-risk group (p&lt;0.05). This risk model also performed well in predicting RFS in TNBC patients, its AUCs for 3-, 4-, and 5-year RFS were 0.65, 0.67, and 0.71 (<xref ref-type="fig" rid="fig4">Figure 4i</xref>).</p></sec><sec id="s2-5"><title>Analysis of independent prognostic factors</title><p>Further, we performed univariate and multivariate Cox analyses to determine whether the risk score could serve as an independent prognostic factor for TNBC patients compared to other common clinicopathologic factors. In the GSE25066 database, <xref ref-type="fig" rid="fig5">Figure 5a</xref> shows that both the risk factor and stage were significantly associated with TNBC patients' RFS and were independent prognostic factors (p&lt;0.05). In the external validation set, <xref ref-type="fig" rid="fig5">Figure 5b</xref> shows that only the risk factor can be considered as independent prognostic factor in TNBC patients (p&lt;0.05).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Analysis of independent prognostic factors for triple-negative breast cancer patients.</title><p>(<bold>a</bold>) The forest plot showing the results of univariate and multivariate COX regression analysis of risk score, age, grade, and stage in the GSE25066 database. (<bold>b</bold>) The forest plot showing the results of univariate and multivariate COX regression analysis of risk score, grade, and stage in the GSE86166 database.</p><p><supplementary-material id="fig5scode1"><label>Figure 5—source code 1.</label><caption><title>Analysis of independent prognostic factors for triple-negative breast cancer patients.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig5-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title>Correlation of the risk score with immune microenvironment</title><p>Next, we calculated the ImmuneScore, StromalScore, ESTIMATEScore, and TumorPurity for samples in the low- and high-risk groups and compared the differences in scores between the two groups. The results showed that these scores did not differ significantly between the low- and high-risk groups (<xref ref-type="fig" rid="fig6">Figure 6a–f</xref>). Then, based on the CIBERSORT algorithm, we found that T cells CD4 memory activated, NK cells resting, and monocytes had significantly higher proportions in the high-risk group, and the NK cells activated, and mast cells resting had significantly higher proportions in the low-risk group (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). Infiltration of these immune cells may play an important role in the clinical course of TNBC patients.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Analysis of immune microenvironment in low- and high-risk groups.</title><p>(<bold>a–d</bold>) Correlation of the risk score with the ImmuneScore, StromalScore, ESTIMATEScore, and TumorPurity. (<bold>e</bold>) Difference of ImmuneScore, StromalScore, and ESTIMATEScore in low- and high-risk groups. (<bold>f</bold>) Difference of TumorPurity in low- and high-risk groups. (<bold>g</bold>) Difference of immune infiltration score between low- and high-risk groups calculated by CIBERSORT. *p&lt;0.05, **p&lt;0.01, ns: p&gt;0.05.</p><p><supplementary-material id="fig6scode1"><label>Figure 6—source code 1.</label><caption><title>Analysis of immune microenvironment in low- and high-risk groups.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig6-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig6-v1.tif"/></fig></sec><sec id="s2-7"><title>Analysis of clinical response to drugs with the risk score</title><p>Based on the ‘pRRophetic’ R package, we explored the relationship between the risk score and clinical response to 138 drugs and calculated the 50% inhibitory concentration (IC<sub>50</sub>). As a result, 16 of 50 drugs whose clinical response was significantly associated with the risk score were positively associated with the risk score, and the remaining 34 were negatively associated with the risk score. Further, we found that 27 of drugs negatively associated with the risk score had significantly lower IC<sub>50</sub> in the high-risk group, suggesting that patients in the high-risk group may be more sensitive to these drugs, favoring the choice of clinical medication (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). Thirteen drugs positively associated with the risk score had significantly higher IC<sub>50</sub> in the high-risk group than in the low-risk group, suggesting that patients in the high-risk group may be less sensitive to these drugs (<xref ref-type="fig" rid="fig7">Figure 7b</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Correlation analysis between risk score and drug sensitivity.</title><p>(<bold>a</bold>) Box plot showing differences of IC<sub>50</sub> for drugs negatively associated with risk scores in different groups. (<bold>b</bold>) Box plot showing differences of IC<sub>50</sub> for drugs positively associated with risk scores in different groups. (<bold>c</bold>) Box plot showing differences of TIDE scores in different groups. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, ns: p&gt;0.05.</p><p><supplementary-material id="fig7scode1"><label>Figure 7—source code 1.</label><caption><title>Correlation analysis between risk score and drug sensitivity.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100923-fig7-code1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100923-fig7-v1.tif"/></fig><p>Finally, we calculated the tumor immune dysfunction and exclusion (TIDE) scores of patients in the low- and high-risk groups; unfortunately, the TIDE scores were not significantly different between the two groups (<xref ref-type="fig" rid="fig7">Figure 7c</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>TNBC is the most difficult subtype of breast cancer to treat, and survival and efficacy prediction for each individual is a critical step in precision tumor therapy. Several studies have identified ferroptosis-related genes as novel therapeutic targets to enhance treatment efficacy and improve patient prognosis (<xref ref-type="bibr" rid="bib17">Desterke et al., 2023</xref>; <xref ref-type="bibr" rid="bib43">Li et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="bib90">Zhou et al., 2024</xref>). However, to the best of our knowledge, there is a lack of reports on the association of ferroptosis-related genes with prognosis and clinical response to treatment in TNBC. Here, firstly, we revealed ferroptosis-related immune cell clustering in TNBC patients at the single-cell level, demonstrating the ferroptosis heterogeneity in TNBC, which was also supported by other cohorts (<xref ref-type="bibr" rid="bib83">Yang et al., 2023a</xref>). On the basis of the above results, we constructed an ferroptosis-related risk score model based on bulk RNA-seq data, which successfully predicted the RFS of TNBC patients and validated the robustness of the results in various datasets. This is important for the individualized management of TNBC patients. More importantly, the model can also predict the sensitivity to drugs for TNBC patients with different risk stratification to guide physicians in the selection of drugs for different patients, and it has significant clinical application value.</p><p>Understanding the TME in TNBC is essential for improving prognosis and guiding treatment. scRNA-seq enables transcriptomic analysis of individual cells to characterize the cellular diversity in the TME in detail, thereby improving understanding of the disease (<xref ref-type="bibr" rid="bib44">Li et al., 2023</xref>; <xref ref-type="bibr" rid="bib70">Van de Sande et al., 2023</xref>; <xref ref-type="bibr" rid="bib87">Zhai et al., 2023</xref>). In this study, our analysis of scRNA-seq data from TNBC revealed that there are multiple immune cells infiltrating in the TME and interacting frequently with each other, and they may impede or promote tumor progression (<xref ref-type="bibr" rid="bib16">Deepak et al., 2020</xref>). We found that the average expression of ferroptosis-related genes was significantly different in different T-stages of tumors, which might be strongly correlated with patient prognosis. Further, based on ferroptosis-related genes, a higher proportion of T cells and macrophages in the TME were categorized into different subpopulations to reveal the heterogeneity of ferroptosis-related in TNBC. The T_C2 subpopulation was accompanied by a greater infiltration of NK cells. NK cells have rapid and efficient antitumor immunity, and their activity is negatively correlated with breast cancer progression (<xref ref-type="bibr" rid="bib6">Bouzidi et al., 2021</xref>; <xref ref-type="bibr" rid="bib24">Gong et al., 2022a</xref>; <xref ref-type="bibr" rid="bib27">Guillerey et al., 2016</xref>). The relevant results were validated in the dataset GSE25066. TFs are universal regulators of the transcription of many genes and are closely associated with the progression of cancer (<xref ref-type="bibr" rid="bib76">Wang et al., 2023</xref>). The results indicate that TBX21, which exhibits higher activity in NKT cells, is associated with the expression of SLC7A11, and overexpression of SLC7A11 alters the expression of chemokines, resulting in the infiltration of immune cells such as CD8<sup>+</sup> T cells and neutrophils (<xref ref-type="bibr" rid="bib11">Cheng et al., 2022</xref>). It has been reported that RUNX3 induces ferroptosis by activating the ING1/p53/SLC7A11 signaling pathway, thereby inhibiting the growth of gallbladder cancer (<xref ref-type="bibr" rid="bib8">Cai et al., 2023</xref>). Furthermore, PRDM1 and IRF, which exhibit higher activity in CD8<sup>+</sup> T cells, induce ferroptosis in cancer cells by inhibiting the transcription of GPX4 and driving the expression of transferrin receptor, respectively, thereby improving the TME (<xref ref-type="bibr" rid="bib64">Song et al., 2024</xref>; <xref ref-type="bibr" rid="bib79">Wu et al., 2024</xref>). FOLR2, SEPP1, MRC1, LYVE1, SLC40A1, and CD163 were highly expressed in the M_C1 subpopulation. Studies have shown that these markers, which are normally present in mammary macrophages from healthy humans and mice, correlate with a favorable prognosis in breast cancer (<xref ref-type="bibr" rid="bib35">Jäppinen et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Nalio Ramos et al., 2022</xref>; <xref ref-type="bibr" rid="bib74">Wang et al., 2020</xref>). Among them, FOLR2 is positively correlated with antitumor immune players of CD8<sup>+</sup> T cells, DCs, B cells, and tertiary lymphoid structures, and there is a strong correlation between FOLR2 expression and various immune pathways, including T-cell receptor and PD-1 signaling, as well as antigen processing. FOLR2<sup>+</sup> macrophages are an important component in the initiation of antitumor immunity (<xref ref-type="bibr" rid="bib54">Nalio Ramos et al., 2022</xref>). In the M_C2 subpopulation, TREM2, FN1, C3, CXCR4, and SPP1 are highly expressed. It has been shown that these markers are lowly expressed in macrophages of healthy breast tissues and highly expressed in tumor tissues (<xref ref-type="bibr" rid="bib52">Molgora et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Müller et al., 2001</xref>; <xref ref-type="bibr" rid="bib54">Nalio Ramos et al., 2022</xref>). Specifically, the absence of TREM2 reshapes macrophage infiltration, fosters the enrichment and activation of T cells and NK cells, and is correlated with an enhanced response to checkpoint blockade therapy (<xref ref-type="bibr" rid="bib52">Molgora et al., 2020</xref>). In addition, S100A8 and IFI6 were also highly expressed in the M_C2 subpopulation. Studies have reported that a high percentage of S100A8<sup>+</sup> myeloid cell infiltration has been suggested as a potential mechanism for worsening the prognosis of TNBC (<xref ref-type="bibr" rid="bib20">Drews-Elger et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Rigiracciolo et al., 2022</xref>). Furthermore, IFI6 is an interferon-stimulated gene with anti-apoptotic and metastasis-promoting effects (<xref ref-type="bibr" rid="bib15">Davenport et al., 2023</xref>). These findings demonstrate the heterogeneity of the function of iron death-associated macrophage subpopulations, which may play different roles in the antitumor process. In the original literature, <xref ref-type="bibr" rid="bib58">Prabhakaran et al., 2017</xref> classified breast cancer into nine clusters (Ecotypes) based on single-cell characteristics, which exhibited distinct cellular compositions and clinical outcomes. Among them, Ecotypes-2 is primarily composed of LumA and Normal-like tumors, and patients in this group have the best prognosis, whereas Ecotype-3 is enriched with Basal_SC, Cycling, Luminal_Progenitor, and a Basal bulk PAM50 subtype, and patients in this group have the worst prognosis. In comparison, this study focuses on TNBC, which has a poorer prognosis. In the different distributions of T cell and macrophage subtypes in different TNBC patients, the study results revealed that ferroptosis-related TME in TNBC patients may be valuable for patient survival and outcome prediction. In the future, altering the degree of macrophage or T-cell infiltration in different subpopulations could be potentially valuable in improving the prognosis of TNBC patients.</p><p>Intratumor heterogeneity is one of the most important factors contributing to poor clinical outcomes in breast cancer, and ferroptosis is one of the major pathways of activation in highly heterogeneous tumors (<xref ref-type="bibr" rid="bib66">Su et al., 2023</xref>; <xref ref-type="bibr" rid="bib78">Wu et al., 2021</xref>; <xref ref-type="bibr" rid="bib86">Zardavas et al., 2015</xref>). In order to better address the problem of accurately predicting the prognosis of TNBC, we firstly performed the correlation analysis of ferroptosis-related genes with RFS and constructed a risk score model in the publicly available dataset of bulk RNA-seq. TNBC patients were categorized into low- and high-risk groups based on the risk score. In the high-risk group, TNBC patients had higher expression levels of the MIIP, HIST3H2A, CDC25B, TCEB1, HMGCS1, SPC25, TKT, PTTG1, ADA, AK1, and AIMP2 genes. Among them, the cell division cycle 25 (CDC25) family of proteins is dual-specific tyrosine phosphatases responsible including three subtypes, CDC25A, CDC25B, and CDC25C, which are used to regulate cell cycle transitions (<xref ref-type="bibr" rid="bib5">Boutros et al., 2007</xref>; <xref ref-type="bibr" rid="bib9">Cairns et al., 2020</xref>). CDC25B dephosphorylates and activates Cyclin-dependent Kinase 1/Cyclin B (CDK1/Cyclin B), which have been shown to be overexpressed in breast cancer and promote cell cycle progression (<xref ref-type="bibr" rid="bib9">Cairns et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Guo et al., 2022</xref>). Spindle component 25 (SPC25) is a key component of the nuclear division cycle 80 (NDC80) complex, and its high expression promotes tumor cell proliferation by inducing mitotic disorder (<xref ref-type="bibr" rid="bib82">Yang et al., 2022</xref>). A study showed that SPC25 promotes the proliferation of breast cancer cells, and high levels of SPC25 mRNA levels are associated with high recurrence rates and low survival rates in breast cancer patients (<xref ref-type="bibr" rid="bib73">Wang et al., 2019</xref>). Pituitary tumor transforming gene 1 (PTTG1) has been demonstrated to promote proliferation, migration, and invasion of cancer cells and is a gene that promotes breast cancer development (<xref ref-type="bibr" rid="bib59">Qi et al., 2019</xref>). At the mRNA level, PTTG1 is more present in patients with high histologic grade and with lymph node metastasis, is significantly associated with low patient survival, and is a biomarker suggestive of poor prognosis in breast cancer, which may be related to the regulation of the cell cycle by PTTG1 to promote the development of breast cancer cells (<xref ref-type="bibr" rid="bib51">Meng et al., 2020</xref>). In the low-risk group, TNBC patients had higher expression levels of the TMEM160, EWSR1, BCAT2, PNKP, MLEC, SAP30BP, TBL1XR1, STAG1, NR4A1, TNFRSF9, PSD3, and BAD genes. These genes have different roles in regulating the TME in colorectal cancers, bladder cancers, lymphomas, etc., but they have been rarely reported in TNBC (<xref ref-type="bibr" rid="bib14">Dai et al., 2024</xref>; <xref ref-type="bibr" rid="bib41">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Venturutti et al., 2020</xref>). In future studies, these genes are valuable to investigate in the regulation of anti-TNBC.</p><p>In TNBC, we found that the risk score model we constructed had independent predictive power for RFS and the predictive performance of this score was stable in an external validation set. Considering the impact of the tumor immune microenvironment on the prognosis of TNBC patients, we further explored the differences in immune cell infiltration in different subgroups of patients. The results showed that T cells CD4 memory-activated, NK cells resting, and monocytes had higher proportions in the high-risk group. This is in line with previous studies, such as that CXCL7 expressed and released by monocytes can stimulate cancer cell migration, invasion, and metastasis (<xref ref-type="bibr" rid="bib75">Wang et al., 2021</xref>). While in the low-risk group, the proportion of NK cells activated and mast cells resting was higher. It has been suggested that the effect of mast cells on tumor invasiveness may vary among different breast cancer subtypes (<xref ref-type="bibr" rid="bib3">Bense et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Majorini et al., 2020</xref>). Our findings suggest that infiltration of mast cells resting in the TME is more favorable to the prognosis of patients.</p><p>For high-risk TNBC patients, it is crucial to seek more effective drugs for adjuvant therapy in clinical practice. In our study, we found that ABT-263 (navitoclax) and erlotinib exhibited the greatest differences in drug sensitivity among different patient groups. ABT-263 is a mimetic of B-cell lymphoma-2 (BCL-2) homology 3 (BH3) that can increase cellular reactive oxygen species (ROS) levels and induce TNBC cell apoptosis by inhibiting the function of anti-apoptotic proteins (BCL-2, BCL-XL, and BCL-W) (<xref ref-type="bibr" rid="bib40">Lee et al., 2022</xref>; <xref ref-type="bibr" rid="bib55">Oh et al., 2021</xref>). ROS is a key regulatory factor in the occurrence of ferroptosis, and excessive production of ROS can lead to the accumulation of lipid peroxides, ultimately triggering cellular ferroptosis (<xref ref-type="bibr" rid="bib63">Shi et al., 2024</xref>; <xref ref-type="bibr" rid="bib65">Stockwell, 2022</xref>). In addition, erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that exerts its effects by competitively binding to the ATP site within the catalytic domain and inhibiting the phosphorylation of EGFR, thereby improving the progression-free survival of patients with EGFR mutations (<xref ref-type="bibr" rid="bib61">Roberts et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Yue et al., 2018</xref>). Studies have shown that β-Elemene can enhance the sensitivity of EGFR-mutated non-small cell lung cancer to erlotinib by upregulating lncRNA H19 and inducing ferroptosis, providing a new approach to overcoming drug resistance in TNBC (<xref ref-type="bibr" rid="bib80">Xu et al., 2023</xref>). EGFR is a receptor tyrosine kinase that promotes the proliferation and invasion of breast cancer by stimulating multiple oncogenic pathways such as Ras-Raf-MEK-ERK, PI3K-AKT-mTOR, and Src-STAT3 (<xref ref-type="bibr" rid="bib77">Wee and Wang, 2017</xref>). The high sensitivity of high-risk patients to erlotinib may be attributed to the higher expression of EGFR in their tumors. Currently, the treatment of TNBC mainly relies on systemic chemotherapy, while small molecule inhibitors and targeted drugs induce cell death through various pathways, holding great promise for antitumor treatment in high-risk patient groups.</p><p>This study has some limitations. First, this study is based on the analysis of transcriptomic data, and the integration of multi-omics data is needed to improve the predictive performance of the model. Second, this study is a retrospective analysis of a public dataset, and future in vivo, in vitro experiments as well as prospective clinical trials are needed to further validate the research findings.</p><p>In conclusion, this study revealed the TNBC ferroptosis-mediated tumor immune cell clustering based on scRNA-seq data, and the degree of infiltration of different subpopulations of cells had different roles in the prognosis of TNBC patients. On this basis, combined with bulk RNA-seq data, the survival prediction model for TNBC patients was established with excellent predictive performance and stability. The high-risk TNBC patients screened by this prediction model and their sensitive therapeutic drugs can help guide physicians in disease monitoring and precise treatment. The related genes screened also provide important value for TNBC patients to find potential therapeutic targets to improve their prognosis.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R package Seurat</td><td align="left" valign="bottom">Microsoft</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Version 4.1.1</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Patient data collection and processing</title><p>The data used in this study were collected from public datasets. Nine single-cell RNA-seq TNBC samples were obtained from the Gene Expression Omnibus (GEO) database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi</ext-link>) under the accession number GSE176078 (<xref ref-type="bibr" rid="bib78">Wu et al., 2021</xref>; <xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Sample information for triple-negative breast cancer in GSE176078.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Case ID</th><th align="left" valign="bottom">Gender</th><th align="left" valign="bottom">Age</th><th align="left" valign="bottom">T_Stage</th><th align="left" valign="bottom" colspan="2">Subtype by IHC</th></tr></thead><tbody><tr><td align="left" valign="bottom">3946</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">52</td><td align="left" valign="bottom" colspan="2">T2</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">44041</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">35</td><td align="left" valign="bottom" colspan="2">T2</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">4465</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">54</td><td align="left" valign="bottom" colspan="2">T2</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">4495</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">63</td><td align="left" valign="bottom" colspan="2">T1</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">44971</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">49</td><td align="left" valign="bottom" colspan="2">T2</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">44991</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">47</td><td align="left" valign="bottom" colspan="2">NA</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">4513</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">73</td><td align="left" valign="bottom" colspan="2">T3</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">4515</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">67</td><td align="left" valign="bottom" colspan="2">T1</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom">4523</td><td align="left" valign="bottom">Female</td><td align="left" valign="bottom">52</td><td align="left" valign="bottom" colspan="2">T2</td><td align="left" valign="bottom">TNBC</td></tr><tr><td align="left" valign="bottom" colspan="6"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>IHC, immunohistochemistry; TNBC, triple-negative breast cancer.</p></fn></table-wrap-foot></table-wrap><p>To construct the model to predict prognosis and immunotherapy efficacy, bulk RNA-seq datasets and clinicopathological information of TNBC were obtained from the GEO database under the accession number GSE25066 (<xref ref-type="bibr" rid="bib30">Hatzis et al., 2011</xref>). The data for external validation were obtained from the GEO database under the accession number GSE86166 (<xref ref-type="bibr" rid="bib58">Prabhakaran et al., 2017</xref>).</p></sec><sec id="s4-2"><title>Single-cell RNA-seq data processing</title><p>Data were processed using the R package Seurat (v. 4.1.1) for QC. Based on QC metrics suggested in Scanpy tutorial, outlier cells were removed based on relevant feature data (nFeature_RNA, nCount_RNA, percent.mt), that is, cells with less than 200 genes expressed or more than 20% mitochondrial genes counts were filtered out. After quality control, the expression data of each cell was normalized separately using the NormalizeData function and the top 2000 highly variable genes (HVGs) of each cell were identified using the FindVariableFeatures function. To remove batch effects among different samples, we utilized the FindIntegrationAnchors function to find anchor genes and then the reclassified datasets were integrated utilized the IntegrateData function. Data normalization was performed using the ScaleData function in Seurat. The RunPCA function was utilized to reduce the dimension of principal component analysis (PCA) for the first 2000 HVGs screened above.</p></sec><sec id="s4-3"><title>Genes associated with ferroptosis acquiring</title><p>The data of 471 genes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) associated with ferroptosis were collected from the FerrDb website (<ext-link ext-link-type="uri" xlink:href="http://www.zhounan.org/ferrdb/current/">http://www.zhounan.org/ferrdb/current/</ext-link>). Then, from the above genes, screened for genes with expression information in the single-cell matrix of TNBC patients. Firstly, based on the clinical data of the samples, the expression values of ferroptosis-related genes in the same type of samples were averaged and presented in a heatmap. Afterward, the expression values of ferroptosis-related genes were averaged across different cell types and also presented in a heatmap.</p></sec><sec id="s4-4"><title>Cell subtype identification associated with ferroptosis</title><p>Because information of cell type annotation was listed in the original literature of the GSE176078 dataset, the metadata of the original literature was used directly for the next analyses. The R package Seurat (v. 4.1.1) was used to identify cell types and presented results via t-SNE. The NMF is an algorithm based on high-throughput data to identify and cluster out different molecular functional patterns (<xref ref-type="bibr" rid="bib19">Ding et al., 2023</xref>). In this work, subtypes of macrophages and T cells based on genes associated with ferroptosis using the ‘NMF’ R package (v 0.26).</p></sec><sec id="s4-5"><title>Cell–cell communication analysis</title><p>Cell–cell communication mediated by ligand–receptor complexes plays an important role in multiple biological processes (<xref ref-type="bibr" rid="bib21">Efremova et al., 2020</xref>). In this study, the ‘iTALK’ R package was utilized to construct the cellular communication network. First, use the rawParse function to identify the top 50% highly expressed genes for each cell type based on their expression means. Then utilize the FindLR function to identify ligands and receptors among the highly expressed genes. Finally, construct an interaction network based on all the interaction relationships.</p></sec><sec id="s4-6"><title>Pseudotime analysis</title><p>Pseudotime analysis of scRNA-seq snapshot data helps provide an approximate landscape of gene expression dynamics (<xref ref-type="bibr" rid="bib67">Sugihara et al., 2022</xref>). The ‘Monocle’R package (v. 2.28.0) was applied for pseudotime analysis to conduct cellular trajectory. The reduceDimensio function based on the DDRTree algorithm is used to reduce the dimensions of the data. Based on the Progenitor Cell Biology Consortium database (<ext-link ext-link-type="uri" xlink:href="https://www.synapse.org">https://www.synapse.org</ext-link>), the stemness signature was identified via the one-class logistic regression algorithm, then the stemness index of each TNBC cell was calculated by scaling the Spearman correlation coefficients to be between 0 and 1. Eventually, the order Cells function was utilized to sort cells and complete construction of trajectory.</p></sec><sec id="s4-7"><title>Transcriptional factor analysis</title><p>The Single-cell rEgulatory Network Inference and Clustering (SCENIC) tool enables simultaneous gene regulatory network reconstruction and cell-state identification from scRNA-seq data (<xref ref-type="bibr" rid="bib1">Aibar et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Van de Sande et al., 2020</xref>). We utilized the ‘SCENIC’ R package (v.1.3.1) to establish the TFs regulatory network. Specifically, first, co-expression modules are inferred using the ‘GENIE3/GRNBOOST’ function to identify gene set with co-expressed TFs. Next, the indirect targets are pruned from these modules using cis-regulatory motif discovery (cisTarget). Finally, the AUCell algorithm was utilized to evaluate the activity of regulons.</p></sec><sec id="s4-8"><title>Hallmarks gene set enrichment analysis</title><p>Hallmarks gene set enrichment analysis was utilized the ‘irGSEA’ R package (v2.1.5). The ssGSEA algorithm was utilized to conduct differential pathway score between ferroptosis-related immune cell subtypes.</p></sec><sec id="s4-9"><title>Construction and validation of the prognostic model</title><p>First, based on the RFS data of 178 TNBC patients in the GSE25066 database, this study utilized the ‘survival’ (v.3.2–7) and ‘survminer’ (v0.4.8) R package to perform univariate Cox proportional hazards regression analyses on ferroptosis-related genes signature of different immune cell subtypes.</p><p>The genes screened for significant association with RFS in the regression analysis (p&lt;0.01) were utilized to construct a risk factor-based model by the LASSO method implemented in the ‘glmnet’ R package (v.4.0–2). TNBC patients were divided into low- and high-risk groups according to the median risk score, and Kaplan–Meier survival curves were utilized to compare the RFS rates between the two groups, p-value&lt;0.05 was considered to be of significance. To validate the performance of the model, receiver operating characteristic curves were demonstrated and the AUC values were calculated for evaluating 3-, 4-, and 5-year RFS rates of TNBC patients in GSE25066 database. In addition, the GSE86166 was utilized as external validation sets to further verify the robustness of the performance of the constructed model in this study.</p></sec><sec id="s4-10"><title>Immune cells infiltration and drug sensitivity analysis</title><p>Immune cells infiltration is important to the antitumor response, and these cells are diverse among patients (<xref ref-type="bibr" rid="bib33">Iglesias-Escudero et al., 2023</xref>; <xref ref-type="bibr" rid="bib57">Pérez-Romero et al., 2020</xref>). The ‘CIBERSORT’, ‘GSVA’, and ‘TIMER’ R package was utilized to determine the distribution of different immune cell types between low- and high-risk groups. Next, the IC<sub>50</sub> of 138 chemotherapeutic drugs was calculated for each patient using the ‘pRRophetic’ R package (v. 0.5), and drugs significantly associated with the risk score were screened. Finally, we calculated the TIDE score (<ext-link ext-link-type="uri" xlink:href="http://tide.dfci.harvard.edu">http://tide.dfci.harvard.edu</ext-link>.) for each patient and thus analyzed its difference between low- and high-risk groups.</p></sec><sec id="s4-11"><title>Statistical analysis</title><p>The R software (v. 4.1.3) was utilized for all data analysis. Wilcoxon rank-sum test was utilized to analyze associations of continuous variables. Log-rank test was utilized to analyze differences in survival curves between groups. p value &lt;0.05 was considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Investigation, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Formal analysis, Supervision, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study used publicly available, anonymized datasets (GSE176078, GSE25066, GSE86166) approved by original ethics committees. Per repository agreements, no additional ethics approval or consent was needed for secondary analysis of de-identified data.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Univariate Cox regression analysis of ferroptosis-related genes and disease-free survival in patients with triple-negative breast cancer.</title></caption><media xlink:href="elife-100923-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Ferroptosis-related genes.</title></caption><media xlink:href="elife-100923-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-100923-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The current manuscript is a computational study, so no data have been generated for this manuscript. Modelling code is uploaded as figure level Source code.</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Al-Eryani</surname><given-names>G</given-names></name><name><surname>Roden</surname><given-names>DL</given-names></name><name><surname>Junankar</surname><given-names>S</given-names></name><name><surname>SZ</surname><given-names>Wu</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>A single-cell and spatially resolved atlas of human breast cancers</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176078">GSE176078</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Hatzis</surname><given-names>C</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Booser</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25066">GSE25066</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Prabhakaran</surname><given-names>S</given-names></name><name><surname>Rizk</surname><given-names>VT</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86166">GSE86166</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>Our thanks go to the GEO database and the FerrDb website for providing essential data resources. Supported by the National Natural Science Foundation of China (81974268, 82472000, 82304151); Talent Incentive Program, Cancer Hospital Chinese Academy of Medical Sciences (801032247); Cooperation Fund of CHCAMS (CFA202202023); and open project of Beijing Key Laboratory of Tumor Invasion and Metastasis Mechanism, Capital Medical University (2023ZLKF03).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aibar</surname><given-names>S</given-names></name><name><surname>González-Blas</surname><given-names>CB</given-names></name><name><surname>Moerman</surname><given-names>T</given-names></name><name><surname>Huynh-Thu</surname><given-names>VA</given-names></name><name><surname>Imrichova</surname><given-names>H</given-names></name><name><surname>Hulselmans</surname><given-names>G</given-names></name><name><surname>Rambow</surname><given-names>F</given-names></name><name><surname>Marine</surname><given-names>J-C</given-names></name><name><surname>Geurts</surname><given-names>P</given-names></name><name><surname>Aerts</surname><given-names>J</given-names></name><name><surname>van den Oord</surname><given-names>J</given-names></name><name><surname>Atak</surname><given-names>ZK</given-names></name><name><surname>Wouters</surname><given-names>J</given-names></name><name><surname>Aerts</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SCENIC: single-cell regulatory network inference and clustering</article-title><source>Nature Methods</source><volume>14</volume><fpage>1083</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4463</pub-id><pub-id pub-id-type="pmid">28991892</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardia</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>IA</given-names></name><name><surname>Vahdat</surname><given-names>LT</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><name><surname>Isakoff</surname><given-names>SJ</given-names></name><name><surname>Diamond</surname><given-names>JR</given-names></name><name><surname>O’Shaughnessy</surname><given-names>J</given-names></name><name><surname>Moroose</surname><given-names>RL</given-names></name><name><surname>Santin</surname><given-names>AD</given-names></name><name><surname>Abramson</surname><given-names>VG</given-names></name><name><surname>Shah</surname><given-names>NC</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Goldenberg</surname><given-names>DM</given-names></name><name><surname>Sweidan</surname><given-names>AM</given-names></name><name><surname>Iannone</surname><given-names>R</given-names></name><name><surname>Washkowitz</surname><given-names>S</given-names></name><name><surname>Sharkey</surname><given-names>RM</given-names></name><name><surname>Wegener</surname><given-names>WA</given-names></name><name><surname>Kalinsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</article-title><source>The New England Journal of Medicine</source><volume>380</volume><fpage>741</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1814213</pub-id><pub-id pub-id-type="pmid">30786188</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bense</surname><given-names>RD</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name><name><surname>Haanen</surname><given-names>JBAG</given-names></name><name><surname>van Vugt</surname><given-names>MATM</given-names></name><name><surname>de Vries</surname><given-names>EGE</given-names></name><name><surname>Schröder</surname><given-names>CP</given-names></name><name><surname>Fehrmann</surname><given-names>RSN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer</article-title><source>Journal of the National Cancer Institute</source><volume>109</volume><elocation-id>djw192</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djw192</pub-id><pub-id pub-id-type="pmid">27737921</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>EW</given-names></name><name><surname>Kersten</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Fearon</surname><given-names>DF</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Howcroft</surname><given-names>TK</given-names></name><name><surname>Woodhouse</surname><given-names>EC</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title><source>Nature Medicine</source><volume>24</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0014-x</pub-id><pub-id pub-id-type="pmid">29686425</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutros</surname><given-names>R</given-names></name><name><surname>Lobjois</surname><given-names>V</given-names></name><name><surname>Ducommun</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CDC25 phosphatases in cancer cells: key players? Good targets?</article-title><source>Nature Reviews. Cancer</source><volume>7</volume><fpage>495</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nrc2169</pub-id><pub-id pub-id-type="pmid">17568790</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouzidi</surname><given-names>L</given-names></name><name><surname>Triki</surname><given-names>H</given-names></name><name><surname>Charfi</surname><given-names>S</given-names></name><name><surname>Kridis</surname><given-names>WB</given-names></name><name><surname>Derbel</surname><given-names>M</given-names></name><name><surname>Ayadi</surname><given-names>L</given-names></name><name><surname>Sellami-Boudawara</surname><given-names>T</given-names></name><name><surname>Cherif</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues</article-title><source>Clinical Breast Cancer</source><volume>21</volume><fpage>e738</fpage><lpage>e747</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2021.02.003</pub-id><pub-id pub-id-type="pmid">33727019</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA</source><volume>74</volume><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>DNA methylation of RUNX3 promotes the progression of gallbladder cancer through repressing SLC7A11-mediated ferroptosis</article-title><source>Cellular Signalling</source><volume>108</volume><elocation-id>110710</elocation-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2023.110710</pub-id><pub-id pub-id-type="pmid">37156453</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>J</given-names></name><name><surname>Ly</surname><given-names>RC</given-names></name><name><surname>Niu</surname><given-names>N</given-names></name><name><surname>Kalari</surname><given-names>KR</given-names></name><name><surname>Carlson</surname><given-names>EE</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer</article-title><source>NAR Cancer</source><volume>2</volume><elocation-id>zcaa039</elocation-id><pub-id pub-id-type="doi">10.1093/narcan/zcaa039</pub-id><pub-id pub-id-type="pmid">33385163</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>QE</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>6494</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-34277-7</pub-id><pub-id pub-id-type="pmid">36310235</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Lv</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SLC7A11, a potential therapeutic target through induced ferroptosis in colon adenocarcinoma</article-title><source>Frontiers in Molecular Biosciences</source><volume>9</volume><elocation-id>889688</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2022.889688</pub-id><pub-id pub-id-type="pmid">35517862</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ching</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Garmire</surname><given-names>LX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cox-nnet: An artificial neural network method for prognosis prediction of high-throughput omics data</article-title><source>PLOS Computational Biology</source><volume>14</volume><elocation-id>e1006076</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006076</pub-id><pub-id pub-id-type="pmid">29634719</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortazar</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Untch</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>K</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name><name><surname>Bonnefoi</surname><given-names>H</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name><name><surname>Valagussa</surname><given-names>P</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Prowell</surname><given-names>T</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Perou</surname><given-names>C</given-names></name><name><surname>Blumenthal</surname><given-names>G</given-names></name><name><surname>Blohmer</surname><given-names>J</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Semiglazov</surname><given-names>V</given-names></name><name><surname>Justice</surname><given-names>R</given-names></name><name><surname>Eidtmann</surname><given-names>H</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Sridhara</surname><given-names>R</given-names></name><name><surname>Fasching</surname><given-names>PA</given-names></name><name><surname>Slaets</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Gerber</surname><given-names>B</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names><suffix>Jr</suffix></name><name><surname>Pazdur</surname><given-names>R</given-names></name><name><surname>Ditsch</surname><given-names>N</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><name><surname>Eiermann</surname><given-names>W</given-names></name><name><surname>von Minckwitz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis</article-title><source>The Lancet</source><volume>384</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)62422-8</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Ruan</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer</article-title><source>Cell Communication and Signaling</source><volume>22</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-024-01541-w</pub-id><pub-id pub-id-type="pmid">38454413</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>AM</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Sabti</surname><given-names>F</given-names></name><name><surname>Sabti</surname><given-names>S</given-names></name><name><surname>Shakya</surname><given-names>D</given-names></name><name><surname>Hynds</surname><given-names>DL</given-names></name><name><surname>Cheriyath</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>G1P3/IFI6, an interferon stimulated protein, promotes the association of RAB5<sup>+</sup> endosomes with mitochondria in breast cancer cells</article-title><source>Cell Biology International</source><volume>47</volume><fpage>1868</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1002/cbin.12079</pub-id><pub-id pub-id-type="pmid">37598317</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deepak</surname><given-names>KGK</given-names></name><name><surname>Vempati</surname><given-names>R</given-names></name><name><surname>Nagaraju</surname><given-names>GP</given-names></name><name><surname>Dasari</surname><given-names>VR</given-names></name><name><surname>Nagini</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>DN</given-names></name><name><surname>Malla</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer</article-title><source>Pharmacological Research</source><volume>153</volume><elocation-id>104683</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104683</pub-id><pub-id pub-id-type="pmid">32050092</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desterke</surname><given-names>C</given-names></name><name><surname>Cosialls</surname><given-names>E</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Elhage</surname><given-names>R</given-names></name><name><surname>Duruel</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Hamaï</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Adverse crosstalk between extracellular matrix remodeling and ferroptosis in basal breast cancer</article-title><source>Cells</source><volume>12</volume><elocation-id>2176</elocation-id><pub-id pub-id-type="doi">10.3390/cells12172176</pub-id><pub-id pub-id-type="pmid">37681908</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Visser</surname><given-names>KE</given-names></name><name><surname>Joyce</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth</article-title><source>Cancer Cell</source><volume>41</volume><fpage>374</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.02.016</pub-id><pub-id pub-id-type="pmid">36917948</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The combination of machine learning and untargeted metabolomics identifies the lipid metabolism -related gene CH25H as a potential biomarker in asthma</article-title><source>Inflammation Research</source><volume>72</volume><fpage>1099</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1007/s00011-023-01732-0</pub-id><pub-id pub-id-type="pmid">37081162</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drews-Elger</surname><given-names>K</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Dias</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>TM</given-names></name><name><surname>Dean</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>J</given-names></name><name><surname>Campion-Flora</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>DN</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Rae</surname><given-names>JM</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Berry</surname><given-names>D</given-names></name><name><surname>El-Ashry</surname><given-names>D</given-names></name><name><surname>Lippman</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome</article-title><source>Breast Cancer Research and Treatment</source><volume>148</volume><fpage>41</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/s10549-014-3122-4</pub-id><pub-id pub-id-type="pmid">25270120</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Vento-Tormo</surname><given-names>M</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name><name><surname>Vento-Tormo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes</article-title><source>Nature Protocols</source><volume>15</volume><fpage>1484</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-0292-x</pub-id><pub-id pub-id-type="pmid">32103204</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Ardehali</surname><given-names>H</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease</article-title><source>Nature Reviews. Cardiology</source><volume>20</volume><fpage>7</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00735-4</pub-id><pub-id pub-id-type="pmid">35788564</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Integrating single-cell RNA-seq and bulk RNA-seq to explore prognostic value and immune landscapes of methionine metabolism-related signature in breast cancer</article-title><source>Frontiers in Genetics</source><volume>15</volume><elocation-id>1521269</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2024.1521269</pub-id><pub-id pub-id-type="pmid">39877420</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Ni</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>An injectable epigenetic autophagic modulatory hydrogel for boosting umbilical cord blood NK cell therapy prevents postsurgical relapse of triple-negative breast cancer</article-title><source>Advanced Science</source><volume>9</volume><elocation-id>e2201271</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202201271</pub-id><pub-id pub-id-type="pmid">35712750</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>TQ</given-names></name><name><surname>Jiang</surname><given-names>YZ</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>WT</given-names></name><name><surname>Liu</surname><given-names>MW</given-names></name><name><surname>Li</surname><given-names>DQ</given-names></name><name><surname>Zhang</surname><given-names>BY</given-names></name><name><surname>Du</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>FF</given-names></name><name><surname>Li</surname><given-names>MY</given-names></name><name><surname>Han</surname><given-names>ZL</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>PY</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer</article-title><source>Cell Reports</source><volume>38</volume><elocation-id>110460</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110460</pub-id><pub-id pub-id-type="pmid">35235781</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>C</given-names></name><name><surname>Gong</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Interpretable machine learning model for new-onset atrial fibrillation prediction in critically ill patients: a multi-center study</article-title><source>Critical Care</source><volume>28</volume><elocation-id>349</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-024-05138-0</pub-id><pub-id pub-id-type="pmid">39473013</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillerey</surname><given-names>C</given-names></name><name><surname>Huntington</surname><given-names>ND</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeting natural killer cells in cancer immunotherapy</article-title><source>Nature Immunology</source><volume>17</volume><fpage>1025</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1038/ni.3518</pub-id><pub-id pub-id-type="pmid">27540992</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y-Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J-G</given-names></name><name><surname>Gu</surname><given-names>Y-J</given-names></name><name><surname>Song</surname><given-names>P-P</given-names></name><name><surname>Wang</surname><given-names>S-Y</given-names></name><name><surname>Qian</surname><given-names>X-Y</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression</article-title><source>Experimental Hematology &amp; Oncology</source><volume>11</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1186/s40164-022-00256-3</pub-id><pub-id pub-id-type="pmid">35287752</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hangauer</surname><given-names>MJ</given-names></name><name><surname>Viswanathan</surname><given-names>VS</given-names></name><name><surname>Ryan</surname><given-names>MJ</given-names></name><name><surname>Bole</surname><given-names>D</given-names></name><name><surname>Eaton</surname><given-names>JK</given-names></name><name><surname>Matov</surname><given-names>A</given-names></name><name><surname>Galeas</surname><given-names>J</given-names></name><name><surname>Dhruv</surname><given-names>HD</given-names></name><name><surname>Berens</surname><given-names>ME</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>McManus</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition</article-title><source>Nature</source><volume>551</volume><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/nature24297</pub-id><pub-id pub-id-type="pmid">29088702</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzis</surname><given-names>C</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Booser</surname><given-names>DJ</given-names></name><name><surname>Esserman</surname><given-names>L</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Vidaurre</surname><given-names>T</given-names></name><name><surname>Holmes</surname><given-names>F</given-names></name><name><surname>Souchon</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Cotrina</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>H</given-names></name><name><surname>Hubbard</surname><given-names>R</given-names></name><name><surname>Chacón</surname><given-names>JI</given-names></name><name><surname>Ferrer-Lozano</surname><given-names>J</given-names></name><name><surname>Dyer</surname><given-names>R</given-names></name><name><surname>Buxton</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Andreopoulou</surname><given-names>E</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name><name><surname>Hunt</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Nazario</surname><given-names>A</given-names></name><name><surname>DeMichele</surname><given-names>A</given-names></name><name><surname>O’Shaughnessy</surname><given-names>J</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer</article-title><source>JAMA</source><volume>305</volume><fpage>1873</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.593</pub-id><pub-id pub-id-type="pmid">21558518</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Diao</surname><given-names>LT</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>SJ</given-names></name><name><surname>Xiao</surname><given-names>ZD</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RNA sequencing: new technologies and applications in cancer research</article-title><source>Journal of Hematology &amp; Oncology</source><volume>13</volume><elocation-id>166</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-020-01005-x</pub-id><pub-id pub-id-type="pmid">33276803</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlader</surname><given-names>N</given-names></name><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Kurian</surname><given-names>AW</given-names></name><name><surname>Andridge</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Differences in breast cancer survival by molecular subtypes in the United States</article-title><source>Cosponsored by the American Society of Preventive Oncology</source><volume>27</volume><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-17-0627</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iglesias-Escudero</surname><given-names>M</given-names></name><name><surname>Arias-González</surname><given-names>N</given-names></name><name><surname>Martínez-Cáceres</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Regulatory cells and the effect of cancer immunotherapy</article-title><source>Molecular Cancer</source><volume>22</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-023-01714-0</pub-id><pub-id pub-id-type="pmid">36739406</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janjic</surname><given-names>A</given-names></name><name><surname>Wange</surname><given-names>LE</given-names></name><name><surname>Bagnoli</surname><given-names>JW</given-names></name><name><surname>Geuder</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Richter</surname><given-names>D</given-names></name><name><surname>Vieth</surname><given-names>B</given-names></name><name><surname>Vick</surname><given-names>B</given-names></name><name><surname>Jeremias</surname><given-names>I</given-names></name><name><surname>Ziegenhain</surname><given-names>C</given-names></name><name><surname>Hellmann</surname><given-names>I</given-names></name><name><surname>Enard</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Prime-seq, efficient and powerful bulk RNA sequencing</article-title><source>Genome Biology</source><volume>23</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-022-02660-8</pub-id><pub-id pub-id-type="pmid">35361256</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jäppinen</surname><given-names>N</given-names></name><name><surname>Félix</surname><given-names>I</given-names></name><name><surname>Lokka</surname><given-names>E</given-names></name><name><surname>Tyystjärvi</surname><given-names>S</given-names></name><name><surname>Pynttäri</surname><given-names>A</given-names></name><name><surname>Lahtela</surname><given-names>T</given-names></name><name><surname>Gerke</surname><given-names>H</given-names></name><name><surname>Elima</surname><given-names>K</given-names></name><name><surname>Rantakari</surname><given-names>P</given-names></name><name><surname>Salmi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fetal-derived macrophages dominate in adult mammary glands</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>281</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08065-1</pub-id><pub-id pub-id-type="pmid">30655530</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>TE</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of immunotherapy in triple-negative breast cancer</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>18</volume><fpage>479</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2020.7554</pub-id><pub-id pub-id-type="pmid">32259782</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Sei</surname><given-names>E</given-names></name><name><surname>Brandt</surname><given-names>R</given-names></name><name><surname>Hartman</surname><given-names>J</given-names></name><name><surname>Hatschek</surname><given-names>T</given-names></name><name><surname>Crosetto</surname><given-names>N</given-names></name><name><surname>Foukakis</surname><given-names>T</given-names></name><name><surname>Navin</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing</article-title><source>Cell</source><volume>173</volume><fpage>879</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.041</pub-id><pub-id pub-id-type="pmid">29681456</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Hashimoto</surname><given-names>A</given-names></name><name><surname>Markosyan</surname><given-names>N</given-names></name><name><surname>Tyurin</surname><given-names>VA</given-names></name><name><surname>Tyurina</surname><given-names>YY</given-names></name><name><surname>Kar</surname><given-names>G</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Sehgal</surname><given-names>M</given-names></name><name><surname>Garcia-Gerique</surname><given-names>L</given-names></name><name><surname>Kossenkov</surname><given-names>A</given-names></name><name><surname>Gebregziabher</surname><given-names>BA</given-names></name><name><surname>Tobias</surname><given-names>JW</given-names></name><name><surname>Hicks</surname><given-names>K</given-names></name><name><surname>Halpin</surname><given-names>RA</given-names></name><name><surname>Cvetesic</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Donthireddy</surname><given-names>L</given-names></name><name><surname>Greenberg</surname><given-names>A</given-names></name><name><surname>Nam</surname><given-names>B</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Nefedova</surname><given-names>Y</given-names></name><name><surname>Kagan</surname><given-names>VE</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ferroptosis of tumour neutrophils causes immune suppression in cancer</article-title><source>Nature</source><volume>612</volume><fpage>338</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05443-0</pub-id><pub-id pub-id-type="pmid">36385526</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuksin</surname><given-names>M</given-names></name><name><surname>Morel</surname><given-names>D</given-names></name><name><surname>Aglave</surname><given-names>M</given-names></name><name><surname>Danlos</surname><given-names>FX</given-names></name><name><surname>Marabelle</surname><given-names>A</given-names></name><name><surname>Zinovyev</surname><given-names>A</given-names></name><name><surname>Gautheret</surname><given-names>D</given-names></name><name><surname>Verlingue</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Applications of single-cell and bulk RNA sequencing in onco-immunology</article-title><source>European Journal of Cancer</source><volume>149</volume><fpage>193</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.03.005</pub-id><pub-id pub-id-type="pmid">33866228</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>HO</given-names></name><name><surname>Masudul Haque</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Yoon</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>IC</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Park</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme</article-title><source>International Journal of Oncology</source><volume>60</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.3892/ijo.2021.5292</pub-id><pub-id pub-id-type="pmid">34913076</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>MZ</given-names></name><name><surname>Li</surname><given-names>XX</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>JT</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>YP</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth</article-title><source>Signal Transduction and Targeted Therapy</source><volume>5</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-0168-0</pub-id><pub-id pub-id-type="pmid">32467562</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>XA</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Oesterreich</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>AV</given-names></name><name><surname>Schwartz</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Semi-deconvolution of bulk and single-cell RNA-seq data with application to metastatic progression in breast cancer</article-title><source>Bioinformatics</source><volume>38</volume><fpage>i386</fpage><lpage>i394</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btac262</pub-id><pub-id pub-id-type="pmid">35758822</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Xiang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk</article-title><source>Journal of Hematology &amp; Oncology</source><volume>15</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-021-01223-x</pub-id><pub-id pub-id-type="pmid">34991659</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hubisz</surname><given-names>MJ</given-names></name><name><surname>Earlie</surname><given-names>EM</given-names></name><name><surname>Duran</surname><given-names>MA</given-names></name><name><surname>Hong</surname><given-names>C</given-names></name><name><surname>Varela</surname><given-names>AA</given-names></name><name><surname>Lettera</surname><given-names>E</given-names></name><name><surname>Deyell</surname><given-names>M</given-names></name><name><surname>Tavora</surname><given-names>B</given-names></name><name><surname>Havel</surname><given-names>JJ</given-names></name><name><surname>Phyu</surname><given-names>SM</given-names></name><name><surname>Amin</surname><given-names>AD</given-names></name><name><surname>Budre</surname><given-names>K</given-names></name><name><surname>Kamiya</surname><given-names>E</given-names></name><name><surname>Cavallo</surname><given-names>JA</given-names></name><name><surname>Garris</surname><given-names>C</given-names></name><name><surname>Powell</surname><given-names>S</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Bettigole</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>AJ</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Parkes</surname><given-names>EE</given-names></name><name><surname>Laughney</surname><given-names>AM</given-names></name><name><surname>Bakhoum</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Non-cell-autonomous cancer progression from chromosomal instability</article-title><source>Nature</source><volume>620</volume><fpage>1080</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06464-z</pub-id><pub-id pub-id-type="pmid">37612508</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer</article-title><source>Drug Resistance Updates</source><volume>73</volume><elocation-id>101059</elocation-id><pub-id pub-id-type="doi">10.1016/j.drup.2024.101059</pub-id><pub-id pub-id-type="pmid">38295753</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YJ</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>WJ</given-names></name><name><surname>Zhao</surname><given-names>CY</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The prognostic significance of a novel ferroptosis-related gene model in breast cancer</article-title><source>Annals of Translational Medicine</source><volume>10</volume><elocation-id>184</elocation-id><pub-id pub-id-type="doi">10.21037/atm-22-479</pub-id><pub-id pub-id-type="pmid">35280394</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>P</given-names></name><name><surname>Amemiya</surname><given-names>HM</given-names></name><name><surname>He</surname><given-names>LL</given-names></name><name><surname>Gandhi</surname><given-names>SJ</given-names></name><name><surname>Nicol</surname><given-names>R</given-names></name><name><surname>Bhattacharyya</surname><given-names>RP</given-names></name><name><surname>Smillie</surname><given-names>CS</given-names></name><name><surname>Hung</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Bacterial droplet-based single-cell RNA-seq reveals antibiotic-associated heterogeneous cellular states</article-title><source>Cell</source><volume>186</volume><fpage>877</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.01.002</pub-id><pub-id pub-id-type="pmid">36708705</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majorini</surname><given-names>MT</given-names></name><name><surname>Cancila</surname><given-names>V</given-names></name><name><surname>Rigoni</surname><given-names>A</given-names></name><name><surname>Botti</surname><given-names>L</given-names></name><name><surname>Dugo</surname><given-names>M</given-names></name><name><surname>Triulzi</surname><given-names>T</given-names></name><name><surname>De Cecco</surname><given-names>L</given-names></name><name><surname>Fontanella</surname><given-names>E</given-names></name><name><surname>Jachetti</surname><given-names>E</given-names></name><name><surname>Tagliabue</surname><given-names>E</given-names></name><name><surname>Chiodoni</surname><given-names>C</given-names></name><name><surname>Tripodo</surname><given-names>C</given-names></name><name><surname>Colombo</surname><given-names>MP</given-names></name><name><surname>Lecis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype</article-title><source>Cancer Research</source><volume>80</volume><fpage>2311</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3596</pub-id><pub-id pub-id-type="pmid">32179512</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Hua</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives</article-title><source>Molecular Cancer</source><volume>20</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-021-01428-1</pub-id><pub-id pub-id-type="pmid">34635121</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>S</given-names></name><name><surname>Milo</surname><given-names>T</given-names></name><name><surname>Isaacson</surname><given-names>A</given-names></name><name><surname>Halperin</surname><given-names>C</given-names></name><name><surname>Miyara</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>Y</given-names></name><name><surname>Lior</surname><given-names>C</given-names></name><name><surname>Pevsner-Fischer</surname><given-names>M</given-names></name><name><surname>Tzahor</surname><given-names>E</given-names></name><name><surname>Mayo</surname><given-names>A</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name><name><surname>Scherz-Shouval</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>5810</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-41518-w</pub-id><pub-id pub-id-type="pmid">37726308</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>C</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression</article-title><source>Molecular Medicine</source><volume>26</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/s10020-020-00161-7</pub-id><pub-id pub-id-type="pmid">32272902</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molgora</surname><given-names>M</given-names></name><name><surname>Esaulova</surname><given-names>E</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Brioschi</surname><given-names>S</given-names></name><name><surname>Bugatti</surname><given-names>M</given-names></name><name><surname>Omodei</surname><given-names>AS</given-names></name><name><surname>Ricci</surname><given-names>B</given-names></name><name><surname>Fronick</surname><given-names>C</given-names></name><name><surname>Panda</surname><given-names>SK</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Gubin</surname><given-names>MM</given-names></name><name><surname>Faccio</surname><given-names>R</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy</article-title><source>Cell</source><volume>182</volume><fpage>886</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.013</pub-id><pub-id pub-id-type="pmid">32783918</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Homey</surname><given-names>B</given-names></name><name><surname>Soto</surname><given-names>H</given-names></name><name><surname>Ge</surname><given-names>N</given-names></name><name><surname>Catron</surname><given-names>D</given-names></name><name><surname>Buchanan</surname><given-names>ME</given-names></name><name><surname>McClanahan</surname><given-names>T</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Wagner</surname><given-names>SN</given-names></name><name><surname>Barrera</surname><given-names>JL</given-names></name><name><surname>Mohar</surname><given-names>A</given-names></name><name><surname>Verástegui</surname><given-names>E</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Involvement of chemokine receptors in breast cancer metastasis</article-title><source>Nature</source><volume>410</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/35065016</pub-id><pub-id pub-id-type="pmid">11242036</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalio Ramos</surname><given-names>R</given-names></name><name><surname>Missolo-Koussou</surname><given-names>Y</given-names></name><name><surname>Gerber-Ferder</surname><given-names>Y</given-names></name><name><surname>Bromley</surname><given-names>CP</given-names></name><name><surname>Bugatti</surname><given-names>M</given-names></name><name><surname>Núñez</surname><given-names>NG</given-names></name><name><surname>Tosello Boari</surname><given-names>J</given-names></name><name><surname>Richer</surname><given-names>W</given-names></name><name><surname>Menger</surname><given-names>L</given-names></name><name><surname>Denizeau</surname><given-names>J</given-names></name><name><surname>Sedlik</surname><given-names>C</given-names></name><name><surname>Caudana</surname><given-names>P</given-names></name><name><surname>Kotsias</surname><given-names>F</given-names></name><name><surname>Niborski</surname><given-names>LL</given-names></name><name><surname>Viel</surname><given-names>S</given-names></name><name><surname>Bohec</surname><given-names>M</given-names></name><name><surname>Lameiras</surname><given-names>S</given-names></name><name><surname>Baulande</surname><given-names>S</given-names></name><name><surname>Lesage</surname><given-names>L</given-names></name><name><surname>Nicolas</surname><given-names>A</given-names></name><name><surname>Meseure</surname><given-names>D</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Reyal</surname><given-names>F</given-names></name><name><surname>Dutertre</surname><given-names>C-A</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Vimeux</surname><given-names>L</given-names></name><name><surname>Donnadieu</surname><given-names>E</given-names></name><name><surname>Buttard</surname><given-names>B</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zelenay</surname><given-names>S</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Guermonprez</surname><given-names>P</given-names></name><name><surname>Piaggio</surname><given-names>E</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer</article-title><source>Cell</source><volume>185</volume><fpage>1189</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.02.021</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>HR</given-names></name><name><surname>Min</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Jang</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Sung</surname><given-names>CO</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Jeong</surname><given-names>EM</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X<sub>L</sub> inhibitor ABT-263 in KRAS-mutant colorectal cancers</article-title><source>Cancer Letters</source><volume>497</volume><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.10.018</pub-id><pub-id pub-id-type="pmid">33068701</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer</article-title><source>Frontiers in Endocrinology</source><volume>14</volume><elocation-id>1135297</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2023.1135297</pub-id><pub-id pub-id-type="pmid">36843602</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Romero</surname><given-names>K</given-names></name><name><surname>Rodríguez</surname><given-names>RM</given-names></name><name><surname>Amedei</surname><given-names>A</given-names></name><name><surname>Barceló-Coblijn</surname><given-names>G</given-names></name><name><surname>Lopez</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immune landscape in tumor microenvironment: implications for biomarker development and immunotherapy</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>5521</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21155521</pub-id><pub-id pub-id-type="pmid">32752264</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhakaran</surname><given-names>S</given-names></name><name><surname>Rizk</surname><given-names>VT</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>CH</given-names></name><name><surname>Berglund</surname><given-names>AE</given-names></name><name><surname>Coppola</surname><given-names>D</given-names></name><name><surname>Khalil</surname><given-names>F</given-names></name><name><surname>Mulé</surname><given-names>JJ</given-names></name><name><surname>Soliman</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes</article-title><source>Breast Cancer Research</source><volume>19</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-017-0864-z</pub-id><pub-id pub-id-type="pmid">28629479</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Bai</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Weng</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer</article-title><source>Journal of Cancer</source><volume>10</volume><fpage>6618</fpage><lpage>6634</lpage><pub-id pub-id-type="doi">10.7150/jca.33433</pub-id><pub-id pub-id-type="pmid">31777591</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigiracciolo</surname><given-names>DC</given-names></name><name><surname>Nohata</surname><given-names>N</given-names></name><name><surname>Lappano</surname><given-names>R</given-names></name><name><surname>Cirillo</surname><given-names>F</given-names></name><name><surname>Talia</surname><given-names>M</given-names></name><name><surname>Adame-Garcia</surname><given-names>SR</given-names></name><name><surname>Arang</surname><given-names>N</given-names></name><name><surname>Lubrano</surname><given-names>S</given-names></name><name><surname>De Francesco</surname><given-names>EM</given-names></name><name><surname>Belfiore</surname><given-names>A</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name><name><surname>Maggiolini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC)</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>41</volume><elocation-id>193</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-022-02396-0</pub-id><pub-id pub-id-type="pmid">35655319</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>MS</given-names></name><name><surname>Anstine</surname><given-names>LJ</given-names></name><name><surname>Finke</surname><given-names>VS</given-names></name><name><surname>Bryson</surname><given-names>BL</given-names></name><name><surname>Webb</surname><given-names>BM</given-names></name><name><surname>Weber-Bonk</surname><given-names>KL</given-names></name><name><surname>Seachrist</surname><given-names>DD</given-names></name><name><surname>Majmudar</surname><given-names>PR</given-names></name><name><surname>Keri</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene</article-title><source>Breast Cancer Research</source><volume>22</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-020-01305-7</pub-id><pub-id pub-id-type="pmid">32552913</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>JH</given-names></name><name><surname>Ballman</surname><given-names>K</given-names></name><name><surname>Polley</surname><given-names>M-YC</given-names></name><name><surname>Campbell</surname><given-names>JD</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Selitsky</surname><given-names>S</given-names></name><name><surname>Fernandez-Martinez</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Soloway</surname><given-names>MG</given-names></name><name><surname>Spears</surname><given-names>PA</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><name><surname>Somlo</surname><given-names>G</given-names></name><name><surname>Port</surname><given-names>ER</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Kuzma</surname><given-names>C</given-names></name><name><surname>Mamounas</surname><given-names>E</given-names></name><name><surname>Golshan</surname><given-names>M</given-names></name><name><surname>Bellon</surname><given-names>JR</given-names></name><name><surname>Collyar</surname><given-names>D</given-names></name><name><surname>Hahn</surname><given-names>OM</given-names></name><name><surname>Hudis</surname><given-names>CA</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Partridge</surname><given-names>A</given-names></name><name><surname>Hyslop</surname><given-names>T</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sikov</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer</article-title><source>Journal of Clinical Oncology</source><volume>40</volume><fpage>1323</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01506</pub-id><pub-id pub-id-type="pmid">35044810</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Combined exposure of emamectin benzoate and microplastics induces tight junction disorder, immune disorder and inflammation in carp midgut via lysosome/ROS/ferroptosis pathway</article-title><source>Water Research</source><volume>257</volume><elocation-id>121660</elocation-id><pub-id pub-id-type="doi">10.1016/j.watres.2024.121660</pub-id><pub-id pub-id-type="pmid">38688190</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>BX</given-names></name><name><surname>Yang</surname><given-names>QC</given-names></name><name><surname>Liu</surname><given-names>YT</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name><name><surname>Xiong</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>HJ</given-names></name><name><surname>Sun</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma</article-title><source>Cancer Letters</source><volume>588</volume><elocation-id>216727</elocation-id><pub-id pub-id-type="doi">10.1016/j.canlet.2024.216727</pub-id><pub-id pub-id-type="pmid">38431035</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications</article-title><source>Cell</source><volume>185</volume><fpage>2401</fpage><lpage>2421</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.06.003</pub-id><pub-id pub-id-type="pmid">35803244</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>GH</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>RC</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>SY</given-names></name><name><surname>Zhou</surname><given-names>JY</given-names></name><name><surname>Lin</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name><name><surname>Gu</surname><given-names>YJ</given-names></name><name><surname>Jiang</surname><given-names>YZ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets</article-title><source>Science Advances</source><volume>9</volume><elocation-id>eadf0837</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adf0837</pub-id><pub-id pub-id-type="pmid">37801493</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugihara</surname><given-names>R</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Kawahara</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Alignment of single-cell trajectory trees with CAPITAL</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5972</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33681-3</pub-id><pub-id pub-id-type="pmid">36241645</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Paraiso</surname><given-names>K</given-names></name><name><surname>Galvan</surname><given-names>C</given-names></name><name><surname>Sheu</surname><given-names>KM</given-names></name><name><surname>Lay</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>DJL</given-names></name><name><surname>Atefi</surname><given-names>M</given-names></name><name><surname>Shirazi</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Braas</surname><given-names>D</given-names></name><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Palaskas</surname><given-names>N</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress</article-title><source>Cancer Cell</source><volume>33</volume><fpage>890</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.017</pub-id><pub-id pub-id-type="pmid">29657129</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Sande</surname><given-names>B</given-names></name><name><surname>Flerin</surname><given-names>C</given-names></name><name><surname>Davie</surname><given-names>K</given-names></name><name><surname>De Waegeneer</surname><given-names>M</given-names></name><name><surname>Hulselmans</surname><given-names>G</given-names></name><name><surname>Aibar</surname><given-names>S</given-names></name><name><surname>Seurinck</surname><given-names>R</given-names></name><name><surname>Saelens</surname><given-names>W</given-names></name><name><surname>Cannoodt</surname><given-names>R</given-names></name><name><surname>Rouchon</surname><given-names>Q</given-names></name><name><surname>Verbeiren</surname><given-names>T</given-names></name><name><surname>De Maeyer</surname><given-names>D</given-names></name><name><surname>Reumers</surname><given-names>J</given-names></name><name><surname>Saeys</surname><given-names>Y</given-names></name><name><surname>Aerts</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A scalable SCENIC workflow for single-cell gene regulatory network analysis</article-title><source>Nature Protocols</source><volume>15</volume><fpage>2247</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-0336-2</pub-id><pub-id pub-id-type="pmid">32561888</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Sande</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Mutasa-Gottgens</surname><given-names>E</given-names></name><name><surname>Naughton</surname><given-names>B</given-names></name><name><surname>Bacon</surname><given-names>W</given-names></name><name><surname>Manning</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pollard</surname><given-names>J</given-names></name><name><surname>Mendez</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Khaladkar</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Leach</surname><given-names>A</given-names></name><name><surname>Ferran</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Applications of single-cell RNA sequencing in drug discovery and development</article-title><source>Nature Reviews. Drug Discovery</source><volume>22</volume><fpage>496</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00688-4</pub-id><pub-id pub-id-type="pmid">37117846</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturutti</surname><given-names>L</given-names></name><name><surname>Teater</surname><given-names>M</given-names></name><name><surname>Zhai</surname><given-names>A</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Babiker</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Béguelin</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>TC</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Chin</surname><given-names>CR</given-names></name><name><surname>Yewdell</surname><given-names>WT</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Phillip</surname><given-names>JM</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Chaudhuri</surname><given-names>J</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Farinha</surname><given-names>P</given-names></name><name><surname>Weng</surname><given-names>AP</given-names></name><name><surname>Nissen</surname><given-names>MD</given-names></name><name><surname>Steidl</surname><given-names>C</given-names></name><name><surname>Morin</surname><given-names>RD</given-names></name><name><surname>Scott</surname><given-names>DW</given-names></name><name><surname>Privé</surname><given-names>GG</given-names></name><name><surname>Melnick</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate</article-title><source>Cell</source><volume>182</volume><fpage>297</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.049</pub-id><pub-id pub-id-type="pmid">32619424</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viswanathan</surname><given-names>VS</given-names></name><name><surname>Ryan</surname><given-names>MJ</given-names></name><name><surname>Dhruv</surname><given-names>HD</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Eichhoff</surname><given-names>OM</given-names></name><name><surname>Seashore-Ludlow</surname><given-names>B</given-names></name><name><surname>Kaffenberger</surname><given-names>SD</given-names></name><name><surname>Eaton</surname><given-names>JK</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Aguirre</surname><given-names>AJ</given-names></name><name><surname>Viswanathan</surname><given-names>SR</given-names></name><name><surname>Chattopadhyay</surname><given-names>S</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Rees</surname><given-names>MG</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Boskovic</surname><given-names>ZV</given-names></name><name><surname>Javaid</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tseng</surname><given-names>Y-Y</given-names></name><name><surname>Roider</surname><given-names>EM</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Cleary</surname><given-names>JM</given-names></name><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kotz</surname><given-names>JD</given-names></name><name><surname>Hon</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Levesque</surname><given-names>MP</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Berens</surname><given-names>ME</given-names></name><name><surname>Shamji</surname><given-names>AF</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway</article-title><source>Nature</source><volume>547</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nature23007</pub-id><pub-id pub-id-type="pmid">28678785</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Bu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Up-regulation of SPC25 promotes breast cancer</article-title><source>Aging</source><volume>11</volume><fpage>5689</fpage><lpage>5704</lpage><pub-id pub-id-type="doi">10.18632/aging.102153</pub-id><pub-id pub-id-type="pmid">31400751</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chaffee</surname><given-names>TS</given-names></name><name><surname>LaRue</surname><given-names>RS</given-names></name><name><surname>Huggins</surname><given-names>DN</given-names></name><name><surname>Witschen</surname><given-names>PM</given-names></name><name><surname>Ibrahim</surname><given-names>AM</given-names></name><name><surname>Nelson</surname><given-names>AC</given-names></name><name><surname>Machado</surname><given-names>HL</given-names></name><name><surname>Schwertfeger</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tissue-resident macrophages promote extracellular matrix homeostasis in the mammary gland stroma of nulliparous mice</article-title><source>eLife</source><volume>01</volume><elocation-id>e57438</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.57438</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Shen</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Kuo</surname><given-names>WH</given-names></name><name><surname>Kuo</surname><given-names>YT</given-names></name><name><surname>Hsu</surname><given-names>YL</given-names></name><name><surname>Wang</surname><given-names>WC</given-names></name><name><surname>Lin</surname><given-names>KT</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Monocytes secrete CXCL7 to promote breast cancer progression</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>1090</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-04231-4</pub-id><pub-id pub-id-type="pmid">34789744</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>LINC01133 can induce acquired ferroptosis resistance by enhancing the FSP1 mRNA stability through forming the LINC01133-FUS-FSP1 complex</article-title><source>Cell Death &amp; Disease</source><volume>14</volume><elocation-id>767</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-023-06311-z</pub-id><pub-id pub-id-type="pmid">38007473</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wee</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Epidermal growth factor receptor cell proliferation signaling pathways</article-title><source>Cancers</source><volume>9</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.3390/cancers9050052</pub-id><pub-id pub-id-type="pmid">28513565</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SZ</given-names></name><name><surname>Al-Eryani</surname><given-names>G</given-names></name><name><surname>Roden</surname><given-names>DL</given-names></name><name><surname>Junankar</surname><given-names>S</given-names></name><name><surname>Harvey</surname><given-names>K</given-names></name><name><surname>Andersson</surname><given-names>A</given-names></name><name><surname>Thennavan</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Torpy</surname><given-names>JR</given-names></name><name><surname>Bartonicek</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Larsson</surname><given-names>L</given-names></name><name><surname>Kaczorowski</surname><given-names>D</given-names></name><name><surname>Weisenfeld</surname><given-names>NI</given-names></name><name><surname>Uytingco</surname><given-names>CR</given-names></name><name><surname>Chew</surname><given-names>JG</given-names></name><name><surname>Bent</surname><given-names>ZW</given-names></name><name><surname>Chan</surname><given-names>C-L</given-names></name><name><surname>Gnanasambandapillai</surname><given-names>V</given-names></name><name><surname>Dutertre</surname><given-names>C-A</given-names></name><name><surname>Gluch</surname><given-names>L</given-names></name><name><surname>Hui</surname><given-names>MN</given-names></name><name><surname>Beith</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>E</given-names></name><name><surname>Segara</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Mak</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>B</given-names></name><name><surname>Warrier</surname><given-names>S</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Millar</surname><given-names>E</given-names></name><name><surname>Powell</surname><given-names>JE</given-names></name><name><surname>Williams</surname><given-names>SR</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>O’Toole</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>E</given-names></name><name><surname>Lundeberg</surname><given-names>J</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Swarbrick</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A single-cell and spatially resolved atlas of human breast cancers</article-title><source>Nature Genetics</source><volume>53</volume><fpage>1334</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00911-1</pub-id><pub-id pub-id-type="pmid">34493872</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Ke</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>PR/SET domain 1 targeting glutathione peroxidase 4 regulates chronic hepatitis B liver fibrosis through ferroptosis</article-title><source>CytoJournal</source><volume>21</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.25259/Cytojournal_123_2024</pub-id><pub-id pub-id-type="pmid">39917009</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>ZB</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>ZM</given-names></name><name><surname>Fan</surname><given-names>XX</given-names></name><name><surname>Sui</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>LL</given-names></name><name><surname>Wang</surname><given-names>XR</given-names></name><name><surname>Zhang</surname><given-names>RN</given-names></name><name><surname>Wang</surname><given-names>WJ</given-names></name><name><surname>Xie</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>YZ</given-names></name><name><surname>Nie</surname><given-names>XW</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>ELH</given-names></name><name><surname>Wu</surname><given-names>QB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer</article-title><source>Pharmacological Research</source><volume>191</volume><elocation-id>106739</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106739</pub-id><pub-id pub-id-type="pmid">36948327</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yam</surname><given-names>C</given-names></name><name><surname>Yen</surname><given-names>E-Y</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Bassett</surname><given-names>RL</given-names></name><name><surname>Alatrash</surname><given-names>G</given-names></name><name><surname>Garber</surname><given-names>H</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Philips</surname><given-names>AV</given-names></name><name><surname>Ding</surname><given-names>Q-Q</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name><name><surname>Kannan</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Parra Cuentas</surname><given-names>ER</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>White</surname><given-names>JB</given-names></name><name><surname>Ravenberg</surname><given-names>E</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Guerriero</surname><given-names>JL</given-names></name><name><surname>Rauch</surname><given-names>GM</given-names></name><name><surname>Damodaran</surname><given-names>S</given-names></name><name><surname>Litton</surname><given-names>JK</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Futreal</surname><given-names>A</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Moulder</surname><given-names>SL</given-names></name><name><surname>Mittendorf</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer</article-title><source>Clinical Cancer Research</source><volume>27</volume><fpage>5365</fpage><lpage>5375</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-0144</pub-id><pub-id pub-id-type="pmid">34253579</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Weng</surname><given-names>D</given-names></name><name><surname>Xiang</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway</article-title><source>International Journal of Biological Sciences</source><volume>18</volume><fpage>5241</fpage><lpage>5259</lpage><pub-id pub-id-type="doi">10.7150/ijbs.71694</pub-id><pub-id pub-id-type="pmid">36147467</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>JH</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>DQ</given-names></name><name><surname>Shi</surname><given-names>JX</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>YP</given-names></name><name><surname>Jiang</surname><given-names>YZ</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy</article-title><source>Cell Metabolism</source><volume>35</volume><fpage>84</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.09.021</pub-id><pub-id pub-id-type="pmid">36257316</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>Q</given-names></name><name><surname>Geng</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>MQ</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors</article-title><source>Breast Cancer Research</source><volume>25</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-023-01703-7</pub-id><pub-id pub-id-type="pmid">37644609</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Mao</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial</article-title><source>The Lancet. Respiratory Medicine</source><volume>6</volume><fpage>863</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30277-7</pub-id><pub-id pub-id-type="pmid">30150014</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zardavas</surname><given-names>D</given-names></name><name><surname>Irrthum</surname><given-names>A</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clinical management of breast cancer heterogeneity</article-title><source>Nature Reviews. Clinical Oncology</source><volume>12</volume><fpage>381</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2015.73</pub-id><pub-id pub-id-type="pmid">25895611</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Single-cell RNA sequencing integrated with bulk RNA sequencing analysis reveals diagnostic and prognostic signatures and immunoinfiltration in gastric cancer</article-title><source>Computers in Biology and Medicine</source><volume>163</volume><elocation-id>107239</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107239</pub-id><pub-id pub-id-type="pmid">37450965</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer</article-title><source>Theranostics</source><volume>11</volume><fpage>3167</fpage><lpage>3182</lpage><pub-id pub-id-type="doi">10.7150/thno.52028</pub-id><pub-id pub-id-type="pmid">33537080</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Integrating bulk and single-cell RNA-seq to construct a macrophage-related prognostic model for prognostic stratification in triple-negative breast cancer</article-title><source>Journal of Cancer</source><volume>15</volume><fpage>6002</fpage><lpage>6015</lpage><pub-id pub-id-type="doi">10.7150/jca.101042</pub-id><pub-id pub-id-type="pmid">39440065</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>TJ</given-names></name><name><surname>Zhang</surname><given-names>MM</given-names></name><name><surname>Liu</surname><given-names>DM</given-names></name><name><surname>Huang</surname><given-names>LL</given-names></name><name><surname>Yu</surname><given-names>HQ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer</article-title><source>Biomaterials</source><volume>305</volume><elocation-id>122447</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122447</pub-id><pub-id pub-id-type="pmid">38154441</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100923.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023hj5876</institution-id><institution>Dalian University of Technology</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This study presents a <bold>useful</bold> finding for the ferroptosis-mediated tumor microenvironment (TME) in triple-negative breast cancer (TNBC) using public single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data. The data were collected and analyzed using <bold>solid</bold> and validated methodology and can be used as a starting point for functional studies of TME in TNBC. The work will be of interest to medical biologists working in the field of TNBC.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100923.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This study aims to explore the ferroptosis-related immune landscape of TNBC through the integration of single-cell and bulk RNA sequencing data, followed by the development of a risk prediction model for prognosis and drug response. The authors identified key subpopulations of immune cells within the TME, particularly focusing on T cells and macrophages. Using machine learning algorithms, the authors constructed a ferroptosis-related gene risk score that accurately predicts survival and the potential response to specific drugs in TNBC patients.</p><p>Strengths:</p><p>The study identifies distinct subpopulations of T cells and macrophages with differential expression of ferroptosis-related genes. The clustering of these subpopulations and their correlation with patient prognosis is highly insightful, especially the identification of the TREM2+ and FOLR2+ macrophage subtypes, which are linked to either favorable or poor prognoses. The risk model thus holds potential not only for prognosis but also for guiding treatment selection in personalized oncology.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100923.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Xuantong</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Lishuang</given-names></name><role specific-use="author">Author</role><aff><institution>Beijing Hospital of Traditional Chinese Medicine, Capital Medical University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Di</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Yu</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qian</given-names></name><role specific-use="author">Author</role><aff><institution>Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China</institution><addr-line><named-content content-type="city">Henan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Hao</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yong</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers. Compared to other types of breast cancer, TNBC exhibits highly aggressive clinical characteristics, a greater likelihood of metastasis, poorer clinical outcomes, and lower survival rates. Immunotherapy is an important treatment option for TNBC, but there is significant heterogeneity in treatment response. Therefore, it is crucial to accurately identify immunosuppressive patients before treatment and actively seek more effective therapeutic approaches for TNBC patients.</p><p>Strengths:</p><p>In this work, the authors collected and integrated data from single cells and large volumes of RNA sequencing and RNA-SEQ to analyze the TME landscape mediated by genes associated with iron death. On this basis, the prediction model of prognosis and treatment response of 131 patients was constructed using a machine learning algorithm, which is beneficial to provide individualized and precise treatment guidance for breast cancer patients.</p></disp-quote><p>Thank you for your appreciation of our work. We are encouraged by your positive feedback and will continue to explore new avenues in personalized medicine for breast cancer.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>However, there are still some issues that need to be clarified:</p><p>(1) The description of the research background is too brief and concise, and it is necessary to add some information about the limitations of existing methods and the differences and advantages of this study compared with other published relevant studies, so as to better highlight the necessity and research value of this study.</p></disp-quote><p>Thank you for your suggestions. We have supplemented the research background and compared the differences between this study and other studies, further highlighting the research value of our study.</p><disp-quote content-type="editor-comment"><p>(2) This study is a retrospective analysis of a public data set and lacks experimental validation and prospective experiments to support the results of bioinformatics analysis. This should be added to the acknowledgment of limitations in the study.</p></disp-quote><p>Thank you for the constructive feedback. We also acknowledge that the lack of experimental evidence is one of the limitations of this study. Therefore, we plan to conduct in vivo and in vitro experiments in our future research to support the findings of our bioinformatics analysis, and have already supplemented the relevant content in the limitations of Discussion.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>This study aims to explore the ferroptosis-related immune landscape of TNBC through the integration of single-cell and bulk RNA sequencing data, followed by the development of a risk prediction model for prognosis and drug response. The authors identified key subpopulations of immune cells within the TME, particularly focusing on T cells and macrophages. Using machine learning algorithms, the authors constructed a ferroptosis-related gene risk score that accurately predicts survival and the potential response to specific drugs in TNBC patients.</p><p>Strengths:</p><p>The study identifies distinct subpopulations of T cells and macrophages with differential expression of ferroptosis-related genes. The clustering of these subpopulations and their correlation with patient prognosis is highly insightful, especially the identification of the TREM2+ and FOLR2+ macrophage subtypes, which are linked to either favorable or poor prognoses. The risk model thus holds potential not only for prognosis but also for guiding treatment selection in personalized oncology.</p></disp-quote><p>Thank you for your thorough review and insightful comments.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The study has a relatively small sample size, with only 9 samples analyzed by scRNA-seq. Given the typically high heterogeneity of the tumor microenvironment (TME) in cancer patients, this may affect the accuracy of the conclusions. The scRNA-seq analysis focuses on the expression of ferroptosis-related genes in various cells within the TME. In contrast, bulk RNA sequencing uses data from tumor samples, and the results between the two analyses are not consistent. The bulk RNA sequencing results may not accurately capture the changes happening in the microenvironment.</p></disp-quote><p>Thank you for your constructive feedback. Although this study only included 9 samples, given the limited availability of scRNA-seq datasets for untreated TNBC in public databases, we chose to utilize a dataset that contains a relatively larger number of untreated TNBC samples. We are fully aware of the complexity and high heterogeneity of the TME. Despite the limited sample size, we first conducted rigorous quality control on the data and, based on this, preliminarily revealed the landscape of the TME mediated by ferroptosis-related genes. These findings provide a new perspective for understanding the biological mechanisms underlying the onset and progression of breast cancer. To enhance the reliability and generalizability of our research results, we plan to strive to expand the sample size in future work and consider integrating other omics technologies, such as proteomics and metabolomics, with scRNA-seq data for a more in-depth exploration of the complex interactions within the TME.</p><p>We also agree with your viewpoint that scRNA-seq data reveals gene expression within individual cells, while bulk RNA-seq data reveals the average gene expression in tumor tissues, and there are differences in data acquisition and processing methods between the two. However, we believe that there are also some close connections between them in terms of gene expression levels. By comparing the expression specificity of marker genes for specific cell types in breast cancer tissues, we found that they are correlated with patient prognosis, and the results have been validated in both internal and external validation sets. Thank you once again for your valuable suggestions, which will play an important guiding role in our subsequent research.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>(1) The breast cancer scRNA-seq dataset files of GSE176078 include 10 TNBC primary tumors (DOI:10.1016/j.compbiomed.2023.107066). However, in this study, only 9 cases were listed, please explain the reason for the data exclusion.</p></disp-quote><p>Thank you for your questions. Although it was clearly stated in the original paper that &quot;To elucidate the cellular architecture of breast cancers, we analyzed 26 primary pre-treatment tumors, including 11 ER+, 5 HER2+ and 10 TNBCs, by scRNA-Seq (Supplementary Table 1),&quot; upon downloading and carefully examining the patient information in Supplementary Table 1, we only included 9 patients explicitly labeled as TNBC in our study (<ext-link ext-link-type="uri" xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9044823/#SD1">https://pmc.ncbi.nlm.nih.gov/articles/PMC9044823/#SD1</ext-link>).</p><disp-quote content-type="editor-comment"><p>(2) The description of the technique in the methods section should be more detailed, such as parameter settings, quality control standards, etc.</p></disp-quote><p>Thank you for your valuable suggestions. We have already supplemented the relevant content in the methods section.</p><disp-quote content-type="editor-comment"><p>(3) Please check and correct formatting errors to improve readability, such as lines 176 and 177.</p></disp-quote><p>We were really sorry for our careless mistakes. Thank you for your reminder. We have corrected the “Pseudotime analysis with scRNA-seq data helps to obtain an approximate landscape of gene expression dynamics” into “Pseudotime analysis of scRNA-seq snapshot data helps to provide an approximate landscape of gene expression dynamics”. And we have further checked and revised the formatting errors of the manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) In multiple sections of the paper, abbreviations are used without being defined when first mentioned.</p></disp-quote><p>We were really sorry for our careless mistakes. Thank you for your reminder. We have already added definitions for the abbreviations in both the abstract and the main text.</p><disp-quote content-type="editor-comment"><p>(2) The authors should analyze whether the transcription factors in Figure 2 are correlated with the expression of ferroptosis-related genes.</p></disp-quote><p>Thank you for your valuable feedback. Some transcription factors in Figure 2 correlate with the expression of ferroptosis-related genes, which we have supplemented in the Discussion.</p><disp-quote content-type="editor-comment"><p>(3) Figures 3d and 4e lack explanations for the axis values, and for Figure 4e, is the unit of the y-axis labeled &quot;survival&quot; in days?</p></disp-quote><p>Thank you for your valuable feedback. We apologize for the lack of explanations for the axis values in Figures 3d and 4e and we have made revisions to both figures accordingly. We have noted that the unit &quot;survival&quot; on the y-axis of Figure 4e is in years, and we have already made the necessary supplement to clarify this. Thank you very much for your reminder.</p><disp-quote content-type="editor-comment"><p>(4) The authors conducted their analysis using public databases but did not cite the original literature, nor did they discuss the similarities and differences between their findings and those in the original studies.</p></disp-quote><p>Thank you for your valuable suggestions, and we deeply apologize for our carelessness. We have supplemented the original literature in the references and discussed the differences between this study and the original literature in the Discussion.</p><disp-quote content-type="editor-comment"><p>(5) Some figures, particularly those involving heatmaps and t-SNE plots (e.g., Figures 1 and 3), present dense and complex data that may be challenging for readers to interpret. The heatmaps (Figure 1e-f and 3d) include many genes, but it is unclear how these genes were selected, and the scale of gene expression differences is difficult to interpret. Simplifying these figures by focusing on the most differentially expressed and clinically relevant genes (e.g., those with prognostic value) would improve readability.</p></disp-quote><p>Thank you for your valuable suggestions. The t-SNE plots in Figures 1 and 3 primarily serve as a dimensionality reduction technique to visually present the clustering of multiple cells or samples based on gene expression, aiding readers in quickly identifying cell subpopulations. The heatmaps, on the other hand, are mainly used to showcase the differential expression of ferroptosis-related genes across different clinicopathological classifications and cell subpopulations, with varying shades of color helping readers quickly recognize gene expression differences among different cell subpopulations. The genes included in the heatmaps (Figures 1e-f and 3d) are sourced from the FerrDb website. We have uploaded the list of ferroptosis-related genes used in this study as Supplementary Table 1 and added the relevant steps in Method 2.3.</p><disp-quote content-type="editor-comment"><p>(6) The study analyzes the expression of ferroptosis-related genes in different immune cells within the TME. The authors should discuss how these changes in gene expression may impact the function and behavior of immune cells.</p></disp-quote><p>Thank you for your valuable feedback. We have supplemented the discussion with detailed effects of the main differential genes (FOLR2 and TREM2) on the tumor immune response.</p><disp-quote content-type="editor-comment"><p>(7) The authors analyzed the expression of ferroptosis-related genes in immune cells using single-cell sequencing data. However, they subsequently applied the selected genes to perform a risk factor analysis in tumor cells. Is the expression and function of these genes the same in immune cells and tumor cells? This seems questionable.</p></disp-quote><p>Thank you very much for your suggestion. We also believe that there may be differences in the expression and function of genes between immune cells and tumor cells. However, some genes may exhibit similarities in their expression and function in immune cells and tumor cells, especially within the tumor immune microenvironment, due to the complex and tight interactions between immune cells and tumor cells (as shown in Figures 1d and 2h), and their expression levels can be related to the onset, progression, and prognosis of tumors.</p><disp-quote content-type="editor-comment"><p>(8) While the risk score model based on ferroptosis-related genes is promising, it lacks experimental validation, which weakens the strength of the conclusions. The authors should consider conducting in vitro or in vivo experiments. These functional studies would provide essential evidence to support the model's predictive capability.</p></disp-quote><p>Thank you for the constructive feedback. We fully recognize the importance of conducting functional studies to substantiate the predictive capability of the model. Therefore, we plan to conduct in vitro and in vivo experiments in our future research to provide the necessary evidence and further validate the model's effectiveness.</p><disp-quote content-type="editor-comment"><p>(9) The manuscript predicts sensitivity to 27 drugs based on the risk score, but it lacks mechanistic insight into why patients in the high-risk group might be more responsive to certain drugs. Including a more detailed discussion of the molecular mechanisms underlying this drug sensitivity, particularly linking ferroptosis-related genes to drug metabolism or efficacy, would provide a stronger rationale for the clinical application of these findings.</p></disp-quote><p>Thank you very much for your valuable suggestions. In the discussion, we thoroughly analyzed the mechanism of action of the drugs (ABT-263 and erlotinib) with the greatest difference in sensitivity between high-risk and low-risk groups, as well as their correlation with ferroptosis.</p></body></sub-article></article>